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CHAPTER 1 
INTRODUCTION : 
  Oral route has been one of the most popular routes of drug delivery due to its ease of 
administration, Patient’s compliance, least sterility constraints and flexible design of dosage 
form. Time release technology, also known as sustained release (SR), sustained-action (SA), 
extended-release (ER, XR or XL), time release or timed release, Controlled release (CR), 
modified release (MR) or continuous release (CR) is a mechanism used in pill tablets or capsules 
to dissolve  slowly and release a drug over a prolonged period of time. Different polymers are 
employed due to their In situ gel forming characteristics and their ability to release entrapped 
drug in the specific medium by swelling and cross linking.  
 Usually conventional dosage form produces wide range of fluctuation in drug concentration in 
the bloodstream and tissues with consequent undesirable toxicity and poor efficiency. The 
maintenance of concentration of drug in plasma within therapeutic index is very critical for 
effective treatment. These factors as well as factors such as repetitive dosing and unpredictable 
absorption lead to the concept of oral Sustained release drug delivery systems. Sustained release 
drug delivery system works on many different mechanisms to control the release rate of drugs. 
Developing oral sustained release matrix tablets for drug with constant release rate has always 
been a challenge to the pharmaceutical technologist. Drug release through matrix system is 
determined by Water penetration, Polymer swelling, Drug dissolution, Drug diffusion, Matrix 
erosion have been utilized as formulation approaches. The present article contains brief review 
on various formulation approaches for Sustained release drug delivery system. 
 Over the Past 30 years, as the expense and complications involved in marketing new drug 
entities have increased, with concomitant recognition of the therapeutic advantages of Sustained 
drug delivery, greater attention is being paid on development of oral sustained release drug 
delivery systems. 
 The goal in designing sustained release drug delivery system is to reduce the frequency of the 
dosing, reducing the dose & providing uniform drug delivery. So, Sustained release dosage form  
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is a dosage form that releases one or more drugs continuously in predetermined pattern for a 
fixed period of time, either systemically or locally to specified target organ (1-3). 
 Sustained release dosage forms provide better control of plasma drug levels, less dosage 
frequency, less side effect, increased efficacy and constant delivery. The modified release oral 
delivery system classification is shown in (Figure 1) [3-4]  
Terminology Sustained release drug delivery system [2-4] 
 It includes any drug delivery system achieves release of drug over an extended period of 
time, which not depend on time. Hydrophilic polymer matrix is widely used for formulating an 
Sustained dosage form. The role of ideal drug delivery system is to provide proper amount of 
drug at regular time interval & at right site of action to maintain therapeutic range of drug in 
blood plasma. 
Classification of Modified Release Drug Delivery System  
 The IR drug delivery system lacks some features like dose maintenance, sustained release 
rate & site targeting. The oral Sustained drug delivery has some potential advantage like 
Sustained release rate & dose maintenance in plasma. The SR formulations have some swelling 
polymer or waxes or both which controls the release rate. The use of reservoir system is also well 
known for controlling release rate. 
 
 
 
Classification of Modified Release Drug Delivery System 
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Figure 1.1: Ideal Plasma Concentration Curves For Immediate Release, Zero Order 
Release, Sustained Release 
Advantages of Sustained/Controlled release drug delivery system over the conventional 
dosage form [4] : 
 Reduced dosing frequency. 
 Dose reduction. 
 Improved patient compliance. 
 Constant level of drug concentration in blood plasma. 
 Reduced toxicity due to overdose. 
 Reduces the fluctuation of peak valley concentration. 
 Night time dosing can be avoided.  
Controlled release : 
It includes any drug delivery system which releases the drug pre determined rate over an 
extended period time.  
Limitation of oral conventional dosage form [2-3] : 
 Poor patient compliance, increased chances of missing the dose of a drug with short half 
life for which frequent administration is necessary.  
4 
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 The unavoidable fluctuations of drug concentration may lead to under medication or over 
medication in narrow therapeutic index drug. 
 
Factors affecting the formulation of oral Sustained release drug delivery system : 
1) Physicochemical factors [2-5] : 
1.1) Aqueous Solubility: 
Most of the drugs are weak acids or weak bases Drugs with low water solubility will be difficult 
to incorporate into sustained release mechanism. For a drug with high solubility and rapid 
dissolution rate, it is often quite difficult to retard its dissolution rate. A drug of high water 
solubility can dissolve in water or gastrointestinal fluid readily and tends to release its dosage 
form in a burst and thus is absorbed quickly leading to a sharp increase in the blood drug 
concentration compared to less soluble drug. It is often difficult to incorporate a highly water 
soluble drug in the dosage form and retard the drug release especially when the dose is high. The 
pH dependent solubility particularly in the physiological pH range would be another problem for 
Sustained release formulation because of the variation in the pH throughout the gastrointestinal 
tract and variation in the dissolution rate. The biopharmaceutical classification system (BCS) 
allows estimation of likely contribution of three major factors solubility, dissolution and 
intestinal permeability which affect the oral absorption.  
Class III (High solubility- Low permeability) & Class IV (Low solubility- Low permeability) 
drugs are poor candidates for Sustained release dosage form compound with solubility < 0.1 
mg/ml face significant solubilisation obstacles and often compounds with solubility 10 mg/ml 
present difficulties to solubilisation dosing formulation. In general, highly soluble drugs are 
undesirable for formulation in to a Sustained release product.  
1.2) Partition coefficient (P (o/w)): 
Partition coefficient is defined as the fraction of drug in an oil phase to that of an adjacent 
aqueous phase. Drugs that passes though biological membrane, if partition co-efficient of drug 
influences shows very much bioavailability because lipophillic nature of biological membrane. 
Drugs that have lower partition coefficient are not suitable for oral CR drug delivery system and 
drugs that have higher partition co-efficient are also not suitable for oral SR drug delivery system 
because they will not partition out of the lipid membrane once it gets in the membrane [5].  
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1.3) Drug pKa and ionization at physiological pH: 
Drugs existing largely in ionized form are poor candidates for oral Sustained release drug 
delivery system. Absorption of the unionized drugs are well whereas permeation of ionized drug 
is negligible because the absorption rate of ionized drug is 3 to 4 times less than that of the 
unionized drug. The pKa range for acidic drug whose ionization is pH sensitive is around 3.0-7.5 
and pKa range for basic drug whose ionization is pH sensitive is around 7.0-11.0 are ideal for 
optimum positive absorption. Drug shall be unionized at the site to an extent 0.1-5.0% [2]. 
 1.4) Drug stability: 
Drugs undergo both acid/base hydrolysis and enzymatic degradation when administered oral 
route. If the drug in the solid state the degradation will occur in reduced rate, for the drugs that 
are unstable in stomach that prolong delivery to the entire GI tract are beneficial. If drug is 
administered in extended release dosage form that are unstable in small intestine may 
demonstrate decreased bioavailability. This occurs due to the fact that a greater quantity of drug 
is delivered in small intestine and is being subjected to more degradation [8-10].  
1.5) Molecular size and diffusivity[7] : 
Diffusivity depends on size & shape of the cavities of the membrane. The diffusion co-efficient 
of intermediate molecular weight drug is 100-400 Daltons; through flexible polymer range is 10-
6-10-9 cm2/sec. For drugs having molecular weight > 500 Daltons, the diffusion coefficient in 
many polymers are very less i.e. less than 10-12 cm2/sec. The examples of drugs which are 
difficult to control release rate of medicament from dosage form are proteins and peptides. 
2) Biological factor[2]: 
 The aim of formulating Sustained release product is to place a control on the delivery system. It 
is essential that the rate of release is much slower than the rate of absorption. If we assume the 
transit time of dosage forms in the absorptive areas of GI tract is about 8-12 hours, the maximum 
half-life for absorption should be approximately 3-4 hours. Otherwise the dosage form will pass 
out of absorptive regions before drug release is complete. Therefore, the compounds with lower 
absorption rate constants are poor candidates. Some possible reasons for low extent of absorption 
are poor water solubility, small partition co-efficient, acid hydrolysis and metabolism or its site  
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of absorption. The distribution of drugs in tissues can be important factor in the overall drug 
elimination kinetics. Since it not only lowers the concentration of circulating drug but it also can  
 
be rate limiting in its equilibrium with blood and extra vascular tissue, consequently apparent 
volume of distribution assumes different values depending on time course of drug disposition. 
Drugs with high apparent volume of distribution, which influence the rate of elimination of the 
drug are poor candidate for oral SR drug delivery system.  
For design of sustained release products, formulation scientist must have information on 
disposition of the drug. A drug which extensively metabolizes is not suitable for SR drug 
delivery system. A drug capable of inducing metabolism, inhibiting metabolism, metabolized at 
the site of absorption or first-pass effect is poor candidate for SR delivery, as it could be difficult 
to maintain constant blood level. 
2.1) Half-life: 
The half-life of a drug is an index of its residence time in the body. If the drug has short half life 
(less than 2 hours) the dosage form may contain a prohibitively large quantity of the drug. On the 
other hand, drug with elimination half-life of 8 hours or more are sufficiently controlled in the 
body, when administered in conventional dosage from and Sustained release drug delivery 
system is generally not necessary in such cases. Ideally, the drug should have half-life of 3 to 4 
hours for formulation of drug delivery system [2-5]. 
2.2) Therapeutic index: 
Drugs with low therapeutic index are unsuitable for incorporation in Sustained release 
formulations. If the system fails in the body, dose dumping may occur, which leads to toxicity [5]. 
2.3) Size of dose: 
If the dose of a drug in the conventional dosage form is high, then it is less suitable candidates 
for SRDDS. This is because the size of a unit dose Sustained release oral formulation would 
become too big to administer without difficulty [6]. 
2.4) Absorption window: 
Certain drugs when administered orally are absorbed only from a specific part of gastrointestinal 
tract. This part is referred to as the ‘absorption window’. These candidates are also not suitable 
for SRDDS [7]. 
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2.5) Plasma concentration response relationship: 
Generally, plasma drug concentration is more responsible for pharmacological activity rather 
than dose. But the drug having pharmacological activity independent of plasma concentrations, 
are poor candidate for oral SR drug delivery system [6]. 
2.6) Concentration dependency on transfer of drug: 
Transfer of drug from one compartment to other, if follows zero order kinetic process then such 
drugs are poor candidate for oral SR delivery system. It should be of first order kinetics [7]. 
 
 The (Figure 3) represents various formulation strategies for oral Sustained release drug delivery 
system. 
 I) Diffusion sustained system: Diffusion process shows the movement of drug molecules from 
a region of a higher concentration to one of lower concentration. 
(a).Diffusion reservoir system: 
In this system, a water insoluble polymeric material covers a core of drug. Drug will partition 
into the membrane and exchange with the fluid surrounding the particle or tablet. Additional 
drug will enter the polymer, diffuse to the periphery and exchange with the surrounding media. 
The drug release takes place by diffusion mechanism. The diffusion type reservoir system is 
shown in (Figure 1.2) 
 
Figure 1.2: Schematic Representation of Diffusion Type Reservoir System  
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Advantages: 
 Zero order delivery is possible.  
 Release rates can be modified with polymer type & concentration.  
Disadvantages: 
 Difficult to deliver high molecular weight compound. 
 Generally increased cost per dosage unit.  
 Potential toxicity if dose dumping occurs.  
( b). Diffusion matrix system: 
The matrix system is defined as a well-mixed composite of one or more drugs with 
gelling agent i.e. hydrophilic polymers. Matrix systems are widely used for sustaining the release 
rate. It is the release system which prolongs and controls the release of the drug that is dissolved 
or dispersed [7,18]. A solid drug is dispersed in an insoluble matrix and the rate of release of drug 
is dependent on the rate of drug diffusion and not on the rate of solid dissolution. The diffusion 
type matrix system is shown in (Figure 1.3) 
 
Figure (1.3): Schematic Representation of Diffusion Type Matrix System 
Advantages: 
 Easier to produce than reservoir or encapsulated devices. 
 Versatile, effective and low cost. 
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 Possible to formulate high molecular weight compounds.  
 Increased the stability by protecting the drug from hydrolysis or other derivative changes 
in gastrointestinal tract. 
Disadvantages: 
 The ghost matrix must be removed after the drug has been released.  
 The release rates are affected by various factors such as, food and the rate transit through 
the gut.  
 Cannot provide pure zero order release.  
Types of diffusion matrix system [11]  
The matrix system can be divided into two categories depending on the types of retarding agents 
or polymeric materials.  
(b)  i ) Hydrophobic matrix system 11 
ii) Hydrophilic matrix system 18-20 
iii) Fat-wax matrix system 12-13 
II) Dissolution sustained systems [13-14] : 
A drug with a slow dissolution rate is inherently sustained and for those drugs with high 
water solubility, one can decrease dissolution through appropriate salt or derivative formation. 
These systems are most commonly employed in the production of enteric coated dosage forms. 
To protect the stomach from the effects of drugs such as Aspirin, a coating that dissolves in 
natural or alkaline media is used. This inhibits release of drug from the dosage form until it 
reaches the higher pH of the intestine. In most cases, enteric coated dosage forms are not truly 
sustaining in nature, but serve as a useful function in directing release of the drug to a special 
site. The same approach can be employed for compounds that are degraded by the harsh 
conditions found in the gastric region. 
     a) Soluble reservoir system: 
In this system drug is coated with a given thickness coating, which is slowly dissolved in the 
contents of gastrointestinal tract by alternating layers of drug with the rate controlling coats as 
shown in (Figure 1.4).  
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Figure (1.4): Schematic Representation of Dissolution of Reservoir System  
 
 
 
3) Dissolution- sustained pulsed delivery system [16-17] : 
Amongst Sustained release formulations hydrophilic matrix technology is the most widely used 
due to its following advantages. 
 Provide desired release profile for a wide therapeutic drug category, drug and solubility.  
 Simple and cost effective manufacturing and robust. 
 Patient acceptance. 
 Ease of drug modulation through level, choice of polymeric systems & function coating.  
A hydrophilic matrix tablet consists of mixture of drug, polymer &excipient (filler/diluents as 
well as other excipient) prepared by hydrophilic polymer in the matrix. Formulators often choose 
from a range of hydrophilic polymer as stand alone or in combination with different polymers for 
release rate control.  
III) Ion exchange resins sustained release [27] : 
Ion exchange resins are cross-linked water-insoluble polymers carrying ion sable functional 
groups. The resins have been used in various pharmaceutical applications, primarily for taste 
masking and controlled release systems. In tablet formulations, ion exchange resins have been 
used as disintegrant, because of their swelling ability. It forms irreversible complex with 
ionisable drugs upon prolonged exposure of the drug to the resin. A resin bound drug is removed  
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when appropriate ions are in contact with ion-exchanged groups. The area and length of 
diffusion pathway and the amount of cross-linked polymer in the resin moiety governs the rate of  
drug release. Sriwongjanya et al. has found the effect of ion exchange resin with drug containing 
opposite charge in matrix system. After this investigation they concluded that the release of drug 
containing opposite charge retarded by the addition of ion exchange resin to HPMC-matrices due 
to formation of complex between drug and resin.  
IV) Methods using osmotic pressure [28-29] : 
In this method, the release controlling factor that must be optimized is the osmotic pressure 
gradient between inside the compartment and the external environment. The simplest and most 
predictable way to achieve a constant osmotic pressure is to maintain a saturated solution of 
osmotic agent in the compartment. This technology provides zero order release used for 
hydrophilic drugs. Drug may be osmotically active or combine with osmotically active salt 
e.g.Nacl. Osmotic pressure is the hydrostatic pressure produced by a solution in a space divided 
by a semi permeable membrane due to difference in concentration of solutes. Osmosis is the 
diffusion of fluid through a semi permeable membrane from a solution with a low solute 
concentration to a solution with a higher solute concentration until there is an equal 
concentration of fluid on both sides of the membrane. A semi permeable membrane is placed 
around a tablet, particle or drug solution that allows transport of water into the tablet with 
eventual pumping of drug solution out of the tablet through a small delivery aperture in tablet 
coating. The osmotic systems are classified in major two types, i.e. type-A & type-B.  
 In type-A system, the core contains both, the drug and electrolytes. The electrolytes 
provide osmotic pressure and maintain the rate of drug release.  
 In type-B system, the drug solution is present in a semi permeable membrane surrounded 
by the electrolytes. Both the systems are shown in (Figure 8 & 9) respectively.  
The ODDS can be conveniently classified in to following types: [22-24]  
A) Single chamber osmotic pump  
B) Multi chamber osmotic pump  
C) Specific types  
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Figure (1.5): Type-A osmotic system 
S  
 
V) pH Independent formulations [25-26] : 
Most drugs are either weak acids or weak bases. The release from Sustained release 
formulations is pH dependent. However; buffers such as salts of amino acids, citric acid, phthalic 
acid phosphoric acid or tartaric acid can be added to the formulation to help to maintain a 
constant pH thereby rendering pH independent drug release.  
VI) Altered density formulations [21-22]: 
Several approaches have been developed to prolong the residence time of drug delivery system 
in the gastrointestinal tract. The delivery system remains in the vicinity of the absorption site 
until most, if not all of its drug contents is released. In high density approach, the density of the 
pellets must exceed that of normal stomach content and should therefore be at least 1-4g/cm3. In 
low density approach, the globular shells which have an apparent density lower than that of 
gastric fluid can be used as a carrier of drug for sustained release purpose. This system is 
generally used when, the single dose for the duration of treatment whether for days or weeks as 
with infection, diabetes or hypertension is required. All sustained release technologies and their 
some example shown in (Table 1). 
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Table (1.1) 
S.No 
 
Technoloy 
 
Brandname 
 
Drug  
 
Manufacturer 
1 
 
Diffusion 
controlled release 
 
Welbutrin 
XL 
 
Bupropin 
 
GlaxoSmithKline 
 
2 Matrix system 
tablet 
Ambient CR 
 
ZolpidemTartarate 
 
Sanofi-Aventis 
 
3 Method using ion 
Exchange 
TussionexPennki
netic ER 
suspension 
 
Hydrocodone 
Polistirex&Chlor-
pheneraminePolisti
rex 
UCB Inc 
 
4 Methods 
using 
osmotic 
pressure 
Element
ary 
Osmotic 
Pump 
Efidac 24® 
 
Chlorpheniramine 
Maleate 
Novartis 
 
Push-
Pull 
Osmotic 
Systems 
 
Glucotrol XL® 
 
Glipizide 
 
Pfizer Inc. 
5 pH independent 
formulation 
Inderal® LA 
 
Propranolol HCl 
 
Wyeth Inc. 
 
6 Altered density 
formulation 
 
Modapar 
 
Levodopa 
&Bense-razide 
Roche Products, 
USA 
 
The Sustained release drug delivery system is very helpful in increasing the efficiency of 
the dose, safety of dose as well as the patient compliance. Nowadays, the oral route of 
administration for Sustained release drug delivery system has received more attention due to its 
more flexibility, reduced dosing frequency and better patient compliance.  
14 
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Rationale for selection of micro spheres: 
 Most of the research effort in developing novel drug delivery systems has been focused 
on oral controlled release dosage forms. Among them, in the last decade, multiple unit dosage 
forms, such as micro spheres or micro particles. Have gained in popularity for different reasons 
when compared to non-disintegrating single unit dosage forms. They distribute more uniformly 
in the gastro intestinal tract, resulting in more uniform and reduce local irritation, and also avoid 
the unwanted intestinal retention. 
Micro particles: 
 These are particles with size more than '1' um, containing the polymer. At present, there 
is no universally accepted size range that particles must have in order to be classified as micro 
spheres .however, may workers classify the particles smaller than ' 1 ' um, as Nanoparticles as 
and those more than 1000 um, as micro spheres or micro particles. 
MICROSPHERES: 
30
 Micro spheres as drug carriers have the advantages of both easier administration via 
injection in suspension without surgical implantation and the potential for administration of 
multiple drug in a single injection.Microspheres are solid, spherical particles containing 
dispersed drug molecules, either in solution or crystalline form, among the polymer molecule. 
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Figure (1.6): 
 
Method of Micro sphere preparation31: 
1)coacervation- phase separation 
2)Interfacial polymerization 
3)In-situ polymerization 
4)Solvent evaporation 
5)co acervation induced by temperature change method 
6)solvent extraction 
7)Spray drying 
8)Fluidized bed coating 
9)Multiorifice centrifugal process 
10)Pan coating 
1. Coacervation-Phase separation32:Coacervation is a colloid phenomenon. If one starts 
with a solution of a colloid in an appropriate solvent, then according to the nature of colloid, 
various changes can bring about a reduction of the solubility of the colloid. As a result of this 
reduction a large part of colloid can be separated out into a new phase. The original one phase 
becomes two phases. One is rich and other is poor in colloid concentration. The colloid rich 
phase in a dispersed state appears as amorphous liquid droplets called coacervate droplets. Upon 
standing these coalesce into one clear homogenous colloid-rich liquid layer, known as coacervate 
layer which can be deposited so as to produce the wall material of the resultant particles. 
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2. Simple coacervation: Simpleco acervation involves the use of either a second more-
water soluble polymer or an aqueous non-solvent  for the gelatin. This produces the partial 
dehydration/desolvation of the  gelatin molecules at a room temperature above the gelling point. 
This results in the separation of a liquid gelatin-rich phase in association with an equilibrium 
liquid (gelatin-poor) which under optimum separation conditions can be almost completely 
devoid of gelatin. Simple co acervation can be effected either by induced by adding a strongly 
hydrophilic substance such as alcohol or sodium sulfate33 . 
Figure (1.7): 
 
2. Interfacial polymerization(If p):In this method the particle shell is formed at or in the 
surface of a droplet by polymerization of reactive monomers. If the micro particulate core is 
water-immiscible liquid then a multifunctional monomers dissolved in the core material. This 
solution is dispersed in an aqueous phase containing dispersing agent. A co-reactant is then 
added to the aqueous phase. This produce a rapid polymerization reaction at the interface which 
generates the micro particles shell. 
Advantage: 
 It is a versatile technology able to micro particles a wide range of core material, 
including aqueous solutions, water immiscible liquids and solids. 
17 
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Disadvantage: 
 Because one of the reactants used to create the micro particles shell is dissolved in 
the core material and is free to react with any groups located on core material 
molecules to create new molecules. 
 particle shell is not uniformly deposited around the core.. 
3. In situ polymerization: In a few processes, the direct polymerization of a single 
monomer is carried out on the particle surface. In one process, e.g. cellulose fibers are covered in 
poly ethylene while immersed in try toluene. Usual deposition rates are about 0.5µm/min. 
Coating thickness range 0.2-75µm. The coating is uniform, even over sharp projections35. 
4. Solvent Evaporation Technique(36,37): 
(Emulsification-Evaporation Method) 
This technique is based on the evaporation of the internal phase of an emulsion by 
agitation. Initially,  The coating polymeric material is dissolved in a volatile organic solvent. The 
core to be covered then dispersed in the coating polymer solution to form a suspension or 
emulsion. In the next step, this organic solution is emulsified under agitation in dispersing phase, 
which is immiscible with the organic solvent, which contains the emulsifier. Once the emulsion 
is stabilized, agitation is maintained and the solvent evaporates after diffusing through the 
continuous phase. This result in the formation of micro spheres. On the completion of the 
process, the micro spheres held in the continuous phase are recovered by filtration or 
centrifugation and are washed and dried. 
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Figure (1.8): 
 
Types of solvent evaporation techniques: 
a. Oil in water emulsion. 
b. Water in oil emulsion. 
c. Multiple emulsion, w/o/w: 
Advantages: 
This process is more effective when the water solubility of the drug is high and partitioning 
between the organic phases is dis favourable. 
Mechanism of solvent evaporation: 
This system is characterized by the existence of several interfaces through which mass 
transfer occurs during particle formation, as shown in the below figure; 
Organic solvent of the dispersed phase of the emulsion is eliminated in two stages: 
1. Diffusion of the solvent in the dispersing phase. 
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2.Elimination of the solvent at dispersing phase -air interface. 
The formation of solid micro spheres is brought about by the evaporation of the volatile solvent 
L1 at interface L2/G. During the course of solvent evaporation, a partitioning is produced across 
the interface L1/L2 from the dispersed phase to continuous phase leading to the formation of solid 
micro spheres. 
5. Solvent Extraction Method: As mentioned in the previous method ,the organic solvent of the 
dispersed phase of the emulsion is eliminated in two stages i.e. 
1. Diffusion into continuous phase& 
2. Elimination of solvent at continuous phase-air interface. 
If one uses a continuous phase which will immediately extract the solvent of the dispersed phase, 
the evaporation stage is no longer necessary in microencapsulation. 
6. Co accervation Induced By Temperature Change Method: This process involves 
dissolving ethyl cellulose in the non-ideal solvent cyclohexane at 80°c and gradually cooling the 
solution so that the polymer separates as a liquid co acerbate and encloses particles of core 
material that are dispersed by various agitation in the system. The deposited wall material may 
be hardened by continuing to lower the temperature while maintaining vigorous agitation to 
prevent coalescence of microspheres. When the system reaches 20 to 25°c, the microspheres can 
be filtered and dried. 
7. Spray Drying: Spray drying serves as a microencapsulation technique when an active 
material is  dissolved or suspended in a melt or polymer solution and becomes trapped in the 
dried particle. Coating solidification in the case of spray drying is effected by rapid evaporation 
of  solvent in which the coating material is dissolved. Coating solidification in spray congealing 
methods, however, is accomplished by thermally congealing a molten coating material or by 
solidifying a dissolved coating by introducing the coating -core material mixture into a non 
solvent. Removal of the non solvent or solvent from the coated product is then accomplished by 
sorption, extraction, or evaporation techniques. In practice, Micro spheres formation by spray 
drying is conducted by dispersing core material in coating solution, in which the coating  
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substance is dissolved and in which the core material is insoluble, and then by atomizing the 
mixture into air stream. The air, usually heated , supplies the latent  heat of vaporization required 
to remove the solvent from the coating material , thus forming the micro sphere product38. Micro 
sphere formation by spray congealing can be accomplished with spray drying equipment when 
the protective coating is applied as amelt. Coating solidification is accomplished by spraying the 
hot mixture into a cool air stream. waxes, fatty acids and alcohols, polymers and sugar, which are 
solids at room temperature but melt able at reasonable temperature, are applicable to spray 
congealing techniques. Typically, the particle size of spray congealed products can be accurately 
controlled when spray drying equipment is used, and has been found to be a function of the feed 
rate, the atomizing wheel velocity, dispersion of feed material viscosity, and variables(39). 
Figure (1.9): Spray dryer 
 
Advantage: 
Low cost of method and able to produce large amount of micro spheres. 
Disadvantages: 
This process is limited to coating material soluble in water, but the list of water soluble coating 
material are limited. 
8. Fluidized bed coating (Water Air Suspension): It consists of the dispersing of solid core 
material in a supporting air steam and then spray coating of the air suspended particles. 
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Advantage: 
Able to handle an extremely wide range of coating formulations. 
9. Multiorifice-Centrifugal processes: In this process it utilizes centrifugal forces to hurl a core 
material particle through an enveloping micro particles membrane, there by effecting mechanical 
micro sphere formation. 
10. Pan coating: 
In this pan coating the particles are tumbled in a pan or other device while the coating material is 
applied slowly(40) with respect to micro sphere formation, solid particles greater than 600 µ in 
size are generally considered essential for effective coating, and the process has been extensively 
employed for the preparation of controlled-release beads. Medicaments are usually coated onto 
various spherical substrates such as nonpareil sugar seeds, and then coated with protective layers 
of various polymers.Usually to remove the coating solvent, warm air is passed over the coated 
materials as the coating are being applied in the coating pans. in some cases, final solvent 
removals accomplished in a drying oven(41). 
Figure(1.10) 
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Application of  Micro sphere formation(42,43): 
 To mask the bitter taste of drug like Paracetamol etc 
 Many drugs have been micro sphere formation to reduce gastric and other G.I.tract 
irritation. Sustained release Aspirin preparations have been reported to cause 
significantly less G.I. bleeding then conventional preparations. 
 A liquid can be converted to a pseudo-solid for easy handling and storage. 
e.g.Eprazinone 
 Hygroscopic properties of core materials may be reduced by micro particles 
formation. e.g. Sodium chloride. 
 Carbon tetra chlorides and a number of other substances have been micro sphere 
formulated to reduce their odor and volatility. 
 Micro spheres formation has been employed to provide protection to the core 
materials against atmospheric effects, e.g. vitamin A. 
 Separation of incompatible substance has been achieved by micro particles 
formation. 
 Cell immobilization: In plant cell cultures, Human tissue is turned into bio-artificial 
organs, in continuous fermentation processes. 
 Protection of molecules from other compounds. 
 Drug delivery: Controlled release delivery systems. 
 Quality and safety in food, agricultural & environmental sectors. 
 Beverages production, soil inoculation. 
 In textiles: means of imparting finishes. 
 Protection of liquid crystals. 
44 Micro spheres for medicinal purpose consist of solid, liquid or gaseous drug enveloped 
within a coating or shell. The coating cane be an organic polymer, a hydro colloid, a sugar, a wax 
, a fat, a metal or an inorganic oxide. Depending on the manufacturing process various structure 
are possible within the capsule.  
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45
 Number of different polymers biodegradable as well as non-biodegradable have been 
investigated for the preparation of microspheres.These polymers are natural and synthetic origin 
and also modified natural substance. Synthetic polymers employed as carrier materials are 
methyl methacrylate, acrolein, lactide, glycolide, and their co-polymers, ethylene vinyl acetate 
co-polymer, poly anhydride etc. 
POLYMERS USED:  
Synthetic polymers: 
    Non- biodegradable: 
 Acrolein 
 Glycidyl methacrylate 
 Epoxy polymers 
 Biodegradable 
 Lactide and glycilides and their co polymers 
 Polyalkyl cyano acrylates 
 Poly anhydrides 
Natural materials: 
 Proteins 
 Albumins 
 Gelatin 
 Collagen 
 Carbohydrates 
 Starch 
 Agarose 
 Carrageen 
 Chitosan 
Chemically modified carbohydrates 
o Poly(acryl)dextran 
o Poly(acryl)starch 
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Release mechanisms (46,47&48) 
1. Degradation controlled monolithic system: 
       The drug is dissolved in matrix and is distributed uniformly throughout. The drug is 
strongly attached to the matrix and is released on degradation of the matrix. The diffusion of the 
drug is slow as compared with degradation of the matrix. 
2. Diffusion controlled monolithic system: 
         Here the active agent is released by diffusion prior to or concurrent with the 
degradation of the polymer matrix. Rate of release also depend upon where the polymer degrades 
by homogeneous mechanism. 
3. Diffusion controlled reservoir system: 
          Here the active agent is covered by a rate controlling membrane through which the 
agent diffuses and the membrane erodes only after its delivery is completed. In this case, drug 
release is unaffected by the degradation of the matrix. 
4. Erosion: 
           Erosion of the coat due to pH and enzymatic hydrolysis cures drug release with 
certain coat material like glyceryl mono stearate, beeswax and steryl alcohol etc.  
Diabetic neuropathy57 
Diabetic neuropathy is one of the most common long-term complications in patients with 
diabetes mellitus, with a prevalence of 60-70% in the United States. Treatment options include 
antidepressants, anticonvulsants, tramadol, and capsaicin. These agents are modestly effectivefor 
symptomatic relief, but they do not affect the underlying pathology nor do they slow progression 
of the disease. Epalrestat is an aldose reductase inhibitor that is approved in Japan for the 
improvement of subjective neuropathy symptoms, abnormality of vibration sense, and abnormal 
changes in heart beat associated with diabetic peripheral neuropath. Unlike the current 
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treatment options for diabetic neuropathy, Epalrestat may affect or delay progression of the 
underlying disease process. Data from experimental studies indicate that Epalrestat reduces  
 
sorbitol accumulation in the sciatic nerve, erythrocytes, and ocular tissues in animals, and in 
erythrocytes in humans. Data from six clinical trials were evaluated, and it was determined that 
Epalrestat 50 mg 3 times/day may improve motor and sensory nerve conduction velocity and 
subjective neuropathy symptoms as compared with baseline and placebo.  
EPALRESTAT 
Epalrestat is Oral anti diabetic agent, Aldose reductase inhibitor which is a carboxylic acid 
derivative which inhibits aldose reductase, an enzyme of the sorbitol (polyol) pathway. Under 
hyperglycemic conditions Epalrestat reduces intracellular sorbitol accumulation, which has been 
implicated in the pathogenesis of late-onset complications of diabetes mellitus. Epalrestat150 
mg/day for 12 weeks improved motor and sensory nerve conduction velocity, and vibration 
threshold compared with baseline and placebo in patients with diabetic neuropathy. Subjective 
symptoms including pain, numbness, hyperesthesia, coldness in the extremities, muscular 
weakness, dizziness, and orthostatic fainting were also improved. Similar benefits wereseen in a 
comparison with historical controls. Epalrestat 300 mg/day for 1 or 3 years was also significantly 
superior to placebo or no treatment in improving electroretinogram parameters and photo stress 
recovery time in patients with diabetic retinopathy. Improvements were also documented by 
funduscopy and fluorescein angiography.Epalrestat appeared most effective in patients with less 
severe diabetes mellitus and more recent. Long-term treatment with Epalrestat is well tolerated 
and can effectively delay the progression of diabetic neuropathy and ameliorate the associated 
symptoms of the disease, particularly in subjects with good glycemic control and limited 
microangiopathy. Natural sources reported to inhibit aldose reductase include spinach, cumin 
seeds, fennel seeds, basil leaves, lemon, black pepper, orange, curry leaves, and cinnamon. 
Chemical name of Epalrestat is C15-H13-N-O3-S2 (5-[(Z, E)-β- ethylcinnamylidene]- 4-oxo-2-
thioxo-3-thiazolidineacetic acid) andits molecular weight is 31949. 
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Aldose Reductase Inhibitors 
Aldose reductase (E.C.1.1.1.21), a ubiquitous enzyme which has been identified in brain, kidney, 
liver, lensand skeletal muscle tissue, is an aldo-keto reductase that catalyzes the NADPH-
dependent reduction ofglucose into sorbitol in the first step of the polyol pathway. In turn,  
 
 
sorbitol is converted into fructose bysorbitol dehydrogenase through an NAD+-dependent 
reaction. Although not determinant, the osmotic stress generated by sorbitol accumulation 
 has been proposed as contributing to the development of tissue damage above all in the 
lens.50Moreover, the increase in the NADH/NAD+ ratio promotes the activation of PKC 
isoforms which are found to be crucial mediators of biochemical and functional alterations 
triggered by hyperglycemia. Thus, the oxidative stress triggered by the glucose-oxidation process 
and upheld by increased ALR2 activity is rightly considered to be a major and unifying 
mechanism responsible for the onset of diabetic complications51. Over the last three decades, 
numerous ALR2 inhibitors(ARIs) have been identified; most of them belong to either carboxylic 
acid (such as Epalrestat) or hydantoin (such as sorbinil, fidarestat) classes of compounds51-56.  
However, many of the clinically tested ARIs proved to be inadequate as drug candidates because 
of adverse pharmacokinetics, toxic side effects or low efficacy. At present, Epalrestat is the only 
ARI available on the market. 
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CHAPTER 2 
LITERATURE  SURVEY 
S.B.Jayasural et al.,58 worked on sustained release captopril micro spheres by spherical 
crystallization  technique using acrylic polymers [Eudragit RL 100 & Eudragit RS 100] and ethyl 
cellulose as the matrix. The effect of drug to the polymer ratio and stirring rate on the drug 
release rate was investigated. It was reported that increase in the concentration of the polymer 
decreases the drug release rate significantly. 
Sanjay K .Jain, Subhash pande and S.P. Vyaset al.,59worked on slow release micro 
spheres of propanolol hydro chloride by an emulsion solvent evaporation  technique using 
Eudragit RS 100 and RL 100.The effect of polymer - solvent ratio, drug polymer ratio, stirring 
rate and evaporation temperature were evaluated. 
Biswanath sa et al.,60 worked on sulphamethizole loaded Eudragit RL 100 micro spheres by 
emulsion-solvent evaporation technique with a view to characterize the factors influencing in-
vitro drug release. It was reported that the cross flow of solvent and solute inside the micro 
spheres did not influence the drug release which however was strongly dependent on pH of the 
dissolution media. 
A Nokhodchi et al.,61 worked on the effect of thermal treating on the tensile  strength of 
tablets and release of indomethacin from Eudragit RS &RL matrices 
Stephan  Gibaud et al.,62 worked on Eudragit RS micro spheres containing 3,4- diamino 
pyridine by a solvent-evaporation technique using light mineral oil as continuous phase. 
Khanfar ms and Salem M.S et al.,63worked on kinetics of the release of indomethacin 
from Eudragit RS polymers 
K.N. Shobha Rani  et al.,64 worked on microencapsulated Diclofenac sodium by using 
different polymeric materials viz. albumin, ethyl cellulose, gelatin, calcium alginate and waxes 
and reported that the release of drug from the micro spheres of gelatin and ethyl cellulose was 
significantly retarded. 
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K.P.R. Chowdary et al.,65worked on ethyl cellulose micro spheres of  Glipizide by an 
industrially feasible emulsion solvent evaporation technique and also evaluated in vitro-in vivo 
performance. It was reported that the micro spheres was suitable for parental controlled release. 
 
Uzunkaya.G,  Bergisadi.N et al.,66 formulated sustained release suppositories containing 
indomethacin micro spheres prepared by solvent evaporation method using ethyl cellulose 
polymer. Drug release results were evaluated for kinetic parameters. 
Kruba.R et al.,67 formulated and evaluated the micro capsules of Amindarone by solvent 
evaporation method using ethyl cellulose polymer. The formulation method was based on drug 
polymer ratio. It was concluded that the ethyl cellulose(drug: polymer 1:1) desired controlled 
release a drug. 
S.Madhusudhan et al.,68 worked on developed sustained release formulations of glipizide 
by microencapsulation techniques using rate retarding polymer ethyl cellulose to promote better 
diabetic therapy. 
R.Sathiyasundar et al.,69 worked on Flurbiprofen microspheres by emulsion solvent 
evaporation technique using ethyl cellulose as the polymer drug content and drug 
entrappingefficiency of microspheres, were also studied. 
Giovanni F.Palmieri et al.,70 worked on ketoproton microspheres by emulsion solvent 
evaporation technique at 150 and 600 and then micro encapsulated using different polymer such 
as ethyl cellulose, cellulose acetate, Eudragit RS. The compressibility measurement indicated 
that the microcapsule showed better compaction than the microcapsule showed better 
compaction that corresponding physical mixture and so were easily transformed into tablets. 
Dilip G. Maheshwari and Keval l. Chaudhari  et al.,71worked on Development and Validation 
of UV SpectrophotometricMethod for Simultaneous estimation of Epalrestat and 
Methylcobalamine in the Pharmaceutical Dosage Form A new sensitive, simple, rapid and 
precise spectrophotometric method has been developed forsimultaneous estimation of Epalrestat 
(EPAL) and Methylcobalamine (MEC) in pharmaceutical dosage form.This method was based 
on UVspectrophotometric determination of two drugs, using simultaneous equation 
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method. It involves measurement of absorbance’s at two wavelengths 390nm (Ȝ max of 
Epalrestat (EPAL)) and 354nm (Ȝ max of Methylcobalamine (MEC)) in methanol for the 
simultaneous quantitative determination of Epalrestat and Methylcobalamine in the binary 
mixture without previous separation. The linearity was observedin the concentration range of 3 – 
15 ȝg/ml for Epalrestat and 15-35 ȝg/ml for Methylcobalamine. The accuracyand precision of 
the method was determined and validated statically. The method showed good reproducibility 
and recovery with % RSD less than 2. Method was found to be rapid, specific, precise and 
accurate, can besuccessfully applied for the routine analysis of Epalrestat and Methylcobalamine 
in combined dosage formwithout any interference by the excipient. 
P. S.GOUDANAVAR, R.S.BAGALI, CHANDRASHEKHARA.S ANDS. M.PATIL et 
al.,72worked on Design and Characterization of Dichlofenac sodium micro beads by Ion tropic 
gelation techniques.Sustained release oral product  of Diclofenac sodium prepared by 
ionotropicgelation technique using Sodium alginate alone and combination with Hydroxypropyl 
methyl cellulose,Chitosan, Pectin as release rate modifiers, and investigated for flow behavior, 
particle size, swellingproperties, surface study by SEM, and in vitro drug release potential. While 
increase in theconcentration of sodium alginate and other polymer dispersions increased 
sphericity, size distribution,mean particle size. Drug entrapment efficiency approached nearly 
95%. Increasing calcium chlorideconcentration decreases the mean diameter of the microbeads, 
no appreciable change in morphology,and drug release behaviors. In vitro drug release was 
dependent on the pH of the medium andconcentration of polymer dispersions. Among the nine 
formulation batches F5, F7 and F9 were found toshow optimum sustained effect. The mechanism 
of drug release from the microbeads was found to be 
followed super case-II transport. 
Thulasi V Menon, C.I.Sajeeth et al.,73worked on Formulation And Evaluation Of Sustained 
Release Sodium Alginate Micro beads Of Carvedilolto formulate Carvedilol loaded micro beads 
of sodium alginate using gelatin and pectin as release modifiers by ionotropic gelation method. 
The microbeads were prepared byvarying the concentration of sodium alginate, gelatin and 
pectin. The drug-polymer compatibility was studied byFTIR studies.The prepared microbeads 
were evaluated for swelling ratio, particle size, drug entrapment,Scanning electron microscopy  
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(SEM), bio adhesion study and in-vitrorelease study. Particle size distribution ofboth placebo and 
drug loaded formulations were measured by an optical microscope and particle size of 
optimized beads was determined by SEM. No significant drug-polymer interactions were 
observed in FT-IRstudies. In-vitrodrug release profile of Carvedilol micro beads was examined 
in pH 1.2 N Hydrochloric acid forfirst 2 hours followed by phosphate buffer pH 7.4 for  
 
remaining time.The in vitro wash-off test indicated thatthe sodium alginate micro beads had 
good mucoadhesive properties. The formulated beads had shown higherentrapment efficiency, 
drug loading, low particle size and moisture content. The formulation F3 released 
Carvedilol for longer duration (24 hours) and showed better mucoadhesion. 
E. Chandra Sekhar1, K. Madhusudana Rao2 et al.,74worked on  
Development of Sodium Alginate/(Lignosulfonicacid -g- Acrylamide) IPN Micro Beads for 
Controlled Release of an Anti-Malarial Drug.  NaAlg/(LSA-g-Am) interpenetrating polymeric 
network micro beads were developed by graft polymerization using calcium chloride as 
crosslinker. Pyronaridine drug was loaded into these microbeads via blending method. Various 
formulations were prepared by varying the ratios of LSA/AAm/NaAlg, crosslinker and % of 
pyronaridine loading. Micro beads were characterized by Fourier transforms infrared 
spectroscopy (FTIR), differential scanning calorimetric (DSC), X-ray diffraction (X-RD) and 
Scanning electron microscopy (SEM). DSC and X-RD studies were performed to understand the 
crystalline nature of drug after encapsulation into semi IPN micro beads. SEM images gave the 
beads with smooth surface. FT-IR spectroscopy of microbeads confirms the formation of co-
polymerization and grafting of the polymers. The encapsulation efficiency was found up to 68 %. 
Drug release profiles of the IPN micro beads at pH 7.4 confirmed that micro beads formed are 
pH-sensitive, resulting controlled release of drug during in vitro dissolution experiments. Both 
encapsulation efficiency and release patterns are found to be dependent on the nature of the 
cross-linking agent, amount of drug loading and % of LSA/Am/NaAlg The release was extended 
up to 12h and release rates were fitted to an empirical equation to compute the diffusion 
parameters, which indicated non-Fickian or anomalous trend release of pyronaridine. 
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Sharath Chandra. Seelam, Dhanalakshmi.K, Nagarjuna reddy et al.,75 worked on A simple, 
efficient and reproducible derivative spectrophotometric method was developed for the drug 
Epalrestat in bulk and tablet dosage forms. First derivative spectrophotometric estimation is use 
for the elimination of irrelevant absorption. Epalrestat wasdetermined at 388 nm, 366nm for 
zero, and first order derivatives respectively using methanol as solvent. Linearity was obtained 
within the range of 1-7 ȝg/ml with correlation coefficient of 0.999, and 0.998 for zero and first 
order derivatives. The %recovery forthe proposed method was found to be 100.04-131.06, 
102.31-129.34% indicating no interferences from the tablet excipient. Theresult of analysis was  
validated statistically and recovery studies confirmed the accuracy and precision of the proposed 
method. 
 
VM. Sherina, K. Santhi and C.I. Sajeeth et al.,76 worked an Formulation and Evaluation of 
Sodium Alginate Microbeads as a Carrier for the Controlled Release of Nifedipine. The objective 
of the current investigation is to reduce dosing frequency and improve patient 
compliance by designing and systematically evaluating sustained release micro beads of 
Nifedipine. Frequent administration and variable low bioavailability (40-50%) after oral 
administration are problems of conventional dosage forms of Nifedipine can be attenuated by 
designing it in the form of mucoadhesive microbeads which would prolong the residence time at 
the absorption site to facilitate intimate contact with the absorption surface and thereby improve 
and enhance the bioavailability. Nifedipine-loaded mucoadhesive micro beads were successfully 
prepared by ionotropic gelation and cross linking technique by using sodium alginate as the 
hydrophilic carrier in combination with HPMC and chitosan polymers as drug release modifiers. 
Prepared beads were evaluated for particle size, swelling ratio, drying rate, drug entrapment, bio 
adhesion study, in-vitrorelease, release kinetic and stability study. Particle size distribution of 
both placebo and drug loaded formulations were measured by an optical microscope and particle 
size of optimized beads was determined by SEM. No significant drug-polymer interactions were 
observed in FT-IR studies.In-vitrodrug release profile of Nifedipine micro beads was examined 
in phosphate buffer pH 6.8 and exhibited zero order kinetic followed bysuper caseII-transport. 
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Gayathri S et al.,77 worked on formulation  and Evaluation of Sustained Release Alginate 
microbeads enclosed Gabapentin  The objective of the present study was to develop sustained 
release beads of gabapentin by ion tropicgelation technique by using different proportions of 
sodium alginate, HPMC- E15, K4M, Sodium carboxyl methyl cellulose and pectin. The drug-
polymer compatibility was studied by FTIR and DSC. The obtained microbeads were 
characterized for particle size determination, swelling ratio, drug entrapment, scanning electron 
microscopy (SEM), drug content, in-vitro release, kinetic models and stability studies. The 
prepared beads were found to be optimal in terms of particle size and entrapment efficacy. There 
was no compatibility issues was found to be in prepared microbeads, which were confirmed by 
FTIR and DSC studies. In-vitro drug release profile of microbeads coated with sodium alginate  
and pectin was examined 98.3% of drug release with in 12h. The release data from all the 
formulation was found to fit higuchi model. The release kinetics data indicated that the drug 
release from microbeads was diffusion-controlled and the microbeads were stable in nature. 
From this study, it was concluded that the micro beads of gabapentin could be successfully 
prepared by ionotropic gelation technique with high entrapment efficiency and sustained release 
characteristics. 
P. Janaki Pathi1*, N. Appala Raju et al.,78Formulation of the Estimation of Epalrestat in 
Tablet Dosage Form by RP-HPLC. A simple, precise, rapid and accurate reverse phase HPLC 
method was developed for the estimation of Epalrestat in tablet dosage form. An XTerra(R) C18 
analytical column (250x4.6 mm, 5 ȝm particle size) with mobile phase consisting of mixture of 
buffer (0.03M Potassium Dihydrogen phosphate in water at pH 3.2 with ortho-phosphoric 
acid) and acetonitrile in the gradient program was used. The flow rate was 1.0 ml/min and the 
effluents were monitored at 294 nm. The retention time was 15.9 min. The detector response was 
linear in the concentration of 20- 120 mcg/ml. The respective linear regression equation being y= 
3818.8x-3819. The limit of detection and limit of quantification was 0.005mcg/ml and 
0.015mcg/ml respectively. The percentage assay of Epalrestat was 99.3%. The 
method was validated by determining its accuracy, precision and system suitability. 
Swapon Kumar Birwa's, Sujit Birwa's et al.,79worked an Formulation Development and 
Physico-Chemical Study of Epalrestat Tablet with Improved Bioavailability in Terms 
ofDisintegration and Dissolution Epalrestat is available in tablet dosage form by some local 
manufacturers of Bangladesh. This proposed formulation will provide better efficacy with low  
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price due to cost effective measures have been taken during every steps of development. It is also 
noted by the performance of improved bioavailability specially parameter like lower  
Disintegration Time and greater Dissolution Rate. Other quality control tests (e.g. Thickness, 
Hardness, Friability, Individual Weight and content of active ingredients) were also performed to 
ensure its better tablet properties. The most amazing and attractive thing of my study is that the 
price will be cheaper than local manufacturer of Bangladesh absolutely with better quality 
because of using some cheap but effective excipient which will help greatly for the poor in our 
country. 
 
By Wei Wei, Lian-Yan Wang, Lan Yuan, et al.,80worked on Preparation and Application of 
Novel Microspheres Possessing Autofluorescent PropertiesFluorescent microspheres are widely 
used as biological tracers. In this study, uniformly sized chitosan microspheres crosslinked with 
glutaraldehyde (CG microspheres) and formaldehyde (CF microspheres) are successfully 
prepared by the Shiras Porous Glass (SPG) membrane emulsification technique. Selectively 
reduced CG microspheres (SRCG microspheres) are obtained by NaBH4 reduction. These 
chitosan microspheres are found to exhibit fluorescent properties without conjugation to any 
fluorescent agent. The fluorescence color varies with different crosslinkers and can be modulated 
by further chemical reduction, whereas the fluorescence intensity can be controlled by tuning the 
particle size and degree of crosslinking. The autofluorescence of the microspheres is applied to 
study the phagocytosis of HepG2 cells using the microspheres as novel tracers. 
Quantitative and qualitative evaluations show that these chitosan microspheres serve as bright, 
inert, durable, and extremely photostable tracers. 
Nurten O¨ zdemir,1,* Sefika Ordu,et al., 81worked on Studies of Floating Dosage Forms of 
Furosemide In Vitro and In Vivo Evaluations of Bilayer Tablet Formulations. the design of 
dosage form, bilayer floating tablets were prepared. After dissolution rate studies were 
performed usingthe continuous flow-through cell method, the formulation that provided delivery 
of active material near the target profile was given to six healthy male volunteer subjects, and in 
vivo tests were performed. It was determined by radiographs that floating tablets prepared by 
adding BaSO4 stayed in the stomach for 6 hr. Further, values of the area under the plasma 
concentration-time curve (AUC) obtained with the floating dosage form were about 1.8 times  
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those of the conventional FR tablet in blood analyses; maximum and minimum plasma 
concentrations were also found to be between the desired limits. In urine analyses, the peak 
diuretic effect seen in classical preparations was decreased and prolonged in floating dosage 
forms. Also, a considerably significant correlation was detected between in vivo results and in 
vitro data ofthe dissolution rate, and it was concluded that the modified continuous flow-through 
cell method is usable for in vitro dissolution rate tests of floating dosage forms. 
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CHAPTER 3 
OBJECTIVE OF THE RESEARCH WORK 
Epalrestat is an effective diabetic neuropathy drug used for reliving nerve pain. Because of 
relatively short biological half life, it needs frequent administration to the patient. Hence 
controlled release of this drug is highly desirable. Epalrestat when formulated as microspheres 
eliminate the disadvantages of the controlled release tablets such as Absorption of drug 
irrespective of the feeding state, Minimal potential for dose dumping, shorter lag time and lower 
variability. Selection of right excipient is crucial and important during the development of matrix 
system because there is a chance of drug dumping. Hence different polymers were used to 
control the drug release from the matrix system. In the present study different polymer were 
used. 
The present study was aimed to prepare the micro spheres of Epalrestat using various Eudragit 
and Ethyl cellulose polymer at different drug to polymer concentrations.Eudragit RL 100 and 
Eudragit RS 100 are two copolymers synthesized from acrylic and methacrylic acid esters, 
containing a low level of quaternary ammonium groups. Eudragit RS 100  has a lower content of 
charged groups (4.5–6.8%), and it is considered less permeable to water with respect to the more 
readily permeable Eudragit RL 100  (8.8–12% ammonium groups). Higher permeability of 
Eudragit RL 100 is due to maximum number of quaternary ammonium substitution present in the 
structure of Eudragit RL 100 compared to RS 100 which affects the release behaviour of the 
drug. Ethyl cellulose is hydrophobic in nature; thus, the hydrophobic polymer encapsulates larger 
amount of the drug and hence was used in combination with Eudragit RL and RS 100 to increase 
the encapsulation efficiency and for a better controlled release. Eudragit S- 100 being a pH 
dependent polymer may reduce the impermeability of Ethyl cellulose  by the formation of pores 
in the matrix.  Hence the study was aimed to study the controlling effect of Epalrestat using the 
aforementioned polymers in the microspheres. The micro spheres prepared were evaluated for 
assay encapsulation efficiency, average particle size, in vitro drug release kinetics. The micro 
spheres were evaluated for drug excipient compatibility studies by FT-IR.   
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PLAN OF RESEARCH WORK 
Construction of standard calibration curves: 
           The standard calibration curve of Epalrestat was prepared by methanol & water. 
Preparation of micro spheres: 
          Micro spheres were prepared by using  solvent evaporation method. 
           Formulation of Epalrestat Micro spheres with Ethyl cellulose, Eudragit L 100, Eudragit 
RS 100, Eudragit RL 100  in the ratio of 1:2 drug and polymer. In this same time the three 
different  polymer only changing ratio of 1:1.2:0.8, 1:1.4:0.6, 1:1.6:0.4 & 1:1.8:0.2. 
In vitro drug release studies of prepared micro spheres: 
The in vitro dissolution studies were performed  for the prepared micro spheres using dissolution 
apparatus (LABINDIA, DS 8000, Mumbai, India). 
Kinetic analysis of dissolution data; 
The release rate and mechanism of drug release from the prepared formulations were analyzed 
by fitting the dissolution data into various release models such as : 
a. zero order 
b. First order 
c. Higuchi model 
d. Peppas equation 
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Encapsulation efficiency (EE): 
The percentage entrapment was calculated by using following formula. 
 
Flow property studies: 
       The flow properties of micro spheres which were prepared are studied by  
  angle of repose. 
Particle size distribution of micro spheres: 
Particle size analysis of the micro spheres was done by using optical micro spheres was done by 
using optical microscopy method. 
Scanning electronic microscopy (SEM): 
      Morphological characterization of the microcapsules was done by using scanning electron 
microscope. 
Fourier transforms infrared radiation measurement (FT-IR): 
  The FT-IR spectrums of pure drug, initial formulation were determined  
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CHAPTER 4 
DRUG & POLYMER PROFILE 
Drug profile of epalrestat82 
Epalrestat is a carboxylic acid derivative which inhibits aldose reductase, an enzyme of the 
sorbitol (polyol) pathway. Under hyperglycemic conditions Epalrestat reduces intracellular 
sorbitol accumulation, which has been implicated in the pathogenesis of late-onset complications 
of diabetes mellitus. 
Chemical name: 3-Thiazolidineacetic acid, 5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-
thioxo-,(E,E)-5-((1Z,2E)-2-Methyl-3-phenylpropenylidene)-4-oxo-2-thioxo-3-thiazolidineacetic 
acid 
Molecular formula: C15H13NO3S2 
Molecular Weight: 319.41 
Solubility: Soluble in organic solvent of di chloro methane 
State: orange Red colour 
Melting Point: 210-217 oC 
Mechanism of action: aldose reductase inhibitor used for treatment of diabeticnephropathy. 
Epalrestat suppresses accumulation of sorbitol in nerve by inhibiting aldose reductase, and 
relieves numbness/pain of the hands and feet and leg cramp, etc., 
Marketed products: Kineda 
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Figure (4.1): 
 
EPALRESTAT 
Product Description: 
Epalrestat is an Aldose Reductase Inhibitor. Aldose Reductase is an enzyme which converts 
excess glucose in to sorbitol which may lead to Neuropath 
Mechanism of Action: 
Epalrestat (5-2-methyl-3-phenylpropenylidene]- 4-oxo-2-thioxo-3-thiazolidineacetic acid) is a 
noncompetitive, reversible inhibitor of aldose reductase, an enzyme of the polyol pathway. 
PHSICOCHEMICAL PROFILE 
Pharmacokinetics83 
Indications 
A peak plasma concentration of 3.9 ȝg/ml is reached approximately 1 hour after administration. 
Distribution 
Epalrestat is highly protein bound, with a protein binding rate of 90.1%. 
Metabolism 
Metabolism occurs in the liver by phase 1 and phases 2 reactions. During phase 1 metabolism, 
Epalrestat is metabolized through hydroxylation into two metabolites, monohydroxy and 
dihydroxy compounds. The enzyme responsible for phase 1 metabolism is unknown. These 
compounds are further metabolized by a phase 2 reaction to produce glucuronide and sulfate 
conjugates. 
Pharmacology 
 The sorbitol (polyol) metabolic pathway, an alternative glucose reduction pathway 
involving the enzymes aldose reductase and sorbitol dehydrogenase, is thought to be activated by  
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hyperglycemic conditions. Intracellular accumulation of sorbitol during hyperglycemia is 
considered to be at least partially responsible for the pathogenesis of late-onset complications of 
diabetes mellitus. Epalrestat, an uncompetitive aldose reductase inhibitor, significantly reduces 
intracellular sorbitol accumulation in sciatic nerve, erythrocytes and ocular tissues from animal 
models, and in erythrocytes in humans, with diabetes mellitus, without affecting glucose levels. 
Epalrestat also increased sodium-dependent myoinositol uptake into sciatic nerve tissue in rats 
and skin fibroblasts from patients with diabetes, and attenuated nerve conduction velocity and 
retinal changes commonly seen in patients with diabetic neuropathy and retinopathy, 
respectively. 
 In healthy volunteers, distribution of Epalrestat is rapid and peak plasma concentrations 
are reached 1 to 2 hours after oral doses of 50 to 200mg. The elimination half-life is about 1 
hour, and unchanged Epalrestat and sulphate conjugates of the mono- and dihydroxyphenyl 
metabolites are found in the urine. 
 Excretion 
The unchanged parent drug is excreted in the urine, as are sulfate conjugates of the two 
metabolites. 
Indications 
To reduce the symptoms of Diabetic Peripheral Neuropathy(DPN) such as numbness, 
tingling and burning sensation of the feet and arms. 
Contraindications 
Hypersensitivity to any component of the drug & in severe hepatic insufficiency. 
Drug Interactions 
No established drug interaction. 
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POLYMER PROFILE: 
 
           A polymer, natural or synthetic is a substance that is combined with a drug or other active 
agent to release drug in a pre-designed manner1. The development of NDDS has been made 
possible by the various compatible polymers to modify the release pattern of drug84, 85. Choice of 
polymers always suffering from the problems of non-biocompatible, non-biodegradable and 
expensive and this problem can solve with a polymer of different properties. The basic objective 
of controlled drug release is to achieve more effective therapies by eliminating the potential for 
both under- and overdosing. Other advantages administrations, optimal drug use and increased 
patient complia86. 
ETHYL CELLULOSE 87 
Figure (4.2) 
 
1. Synonyms 
Aqua coat ECD; Aqualon; Ashacel; E462; Ethocel; ethylcellulosum; 
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2.Chemical Name and CAS Registry Number 
Cellulose ethyl ether [9004-57-3] 
3. Empirical Formula and Molecular Weight 
Ethyl cellulose is partially ethoxylated. Ethyl cellulose with completeethoxyl substitution (DS = 
3) isC12H23O6(C12H22O5)nC12H23O5 where n can vary to provide awide variety of 
molecular weights. Ethyl cellulose, an ethyl ether ofcellulose, is a long-chain polymer of b-an 
hydro glucose units joinedtogether by acetyl linkages. 
4.Functional Category 
Coating agent; flavoring agent; tablet binder; tablet filler; viscosity increasing 
agent. 
5.Applications in Pharmaceutical Formulation orTechnology 
Ethyl cellulose is widely used in oral and topical pharmaceutical 
formulations; see Table I. The main use of Ethyl cellulose in oral formulations is as a 
hydrophobic coating agent for tablets and granules. Ethyl `cellulose coatings are used to modify 
the release of a drug, to mask an unpleasant taste, or to improve the stability of a formulation; for 
example, where granules are coated with Ethyl cellulose to inhibit oxidation. Modified-release 
tablet formulations may also be produced using Ethyl cellulose as a matrix former. Ethyl 
cellulose, dissolved in an organic solvent or solvent mixture, can be used on its own to produce 
water-insoluble films. Higher-viscosity Ethyl cellulose grades tend to produce stronger and more 
durable films. Ethyl cellulose films may be modified to alter their solubility, by the addition of 
hypromellose or a plasticizer. 
 An aqueous polymer dispersion(or latex) of Ethyl cellulose such as Aqua coat ECD (FMC 
Biopolymer) or Sure lease (Colorcon) may also be used to produce Ethyl cellulose films without 
the need for organic solvents. Drug release through ethyl cellulose-coated dosage forms can be 
controlled by diffusion through the film coating. This can be a slow process unless a large 
surface area (e.g. pellets or granules compared with tablets) is utilized. In those instances, 
aqueous Ethyl cellulose dispersions are generally used to coat granules or pellets. Ethyl 
cellulose-coated beads and granules have also demonstrated the ability to absorb pressure and 
hence protect the coating from fracture during compression. High-viscosity grades of ethyl  
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cellulose are used in drug microencapsulation. Release of a drug from an ethyl cellulose 
microcapsule is a function of the microcapsule wall thickness and surface area. In tablet 
formulations, ethyl cellulose may additionally be employed as a binder, the ethyl cellulose being 
blended dry or wet granulated with a solvent such as ethanol (95%). Ethyl cellulose produces 
hard tablets with low friability, although they may demonstrate poor dissolution. Ethyl cellulose 
has also been used as an agent for delivering therapeutic agents from oral (e.g. dental) 
appliances. In topical formulations, ethyl cellulose is used as a thickening agent in creams, 
lotions, or gels, provided an appropriate solvent is used. Ethyl cellulose has been studied as a 
stabilizer for emulsions. Ethyl cellulose is additionally used in cosmetics and food products. 
Table I: Uses of ethyl cellulose. 
 Use      Concentration (%) 
 Microencapsulation                                     10.0–20.0 
 Sustained-release tablet coating                  3.0–20.0 
 Tablet coating                                             1.0–3.0 
 Tablet granulation                                       1.0–3.0 
6. Description 
Ethyl cellulose is a tasteless, free-flowing, white to light tan-colored powder. 
 
Figure (4.3) 
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7. Typical Properties 
Density (bulk)0.4 g/cm3 
Glass transition temperature 129–1338C 
Moisture contentEthyl cellulose absorbs very little water from humid air or during immersion, 
and that small amount evaporates readily. 
Solubility 
Ethyl cellulose is practically insoluble in glycerin, propylene glycol, and water. Ethyl cellulose 
that contains less than 46.5% of ethoxyl groups is freely soluble in chloroform, 
methyl acetate, and tetrahydrofuran, and in mixtures of aromatic hydrocarbons with ethanol 
(95%). Ethyl cellulose that contains not less than 46.5% of ethoxyl groups is freely soluble in 
chloroform, ethanol (95%), ethyl acetate, methanol, 
and toluene. 
8.Safety 
Ethyl cellulose is widely used in oral and topical pharmaceutical formulations. It is also used in 
food products. Ethyl cellulose is not metabolized following oral consumption and is therefore a 
no calorific substance. Because ethyl cellulose is not metabolized it is not recommended for 
parenteral products. parenteral use may be harmful to the kidneys.  Ethyl cellulose is generally 
regarded as a nontoxic, nonallergenic, and nonirritating material. As ethyl cellulose is not 
considered to be a health hazard, the WHO has not specified an acceptable daily intake. The 
highest reported level used in an oral product is 308.8 mg in an oral 
sustained release tablet. 
9. Stability and Storage Conditions 
Ethyl cellulose is a stable, slightly hygroscopic material. It is chemically resistant to alkalis, both 
dilute and concentrated, and to salt solutions, although it is more sensitive to acidic materials 
than are cellulose esters. Ethyl cellulose is subject to oxidative degradation in the presence 
of sunlight or UV light at elevated temperatures. This may be prevented by the use of antioxidant 
and chemical additives that absorb light in the 230–340nm range. Ethyl cellulose should be 
stored at a temperature not exceeding 328C (908F) in a dry area away from all sources of heat. It 
should not be stored next to peroxides or other oxidizing agents. 
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10. Incompatibilities 
Incompatible with paraffin wax and microcrystalline wax. 
11. Related Substances 
Hydroxyethyl cellulose; hydroxyethylmethyl cellulose; mEthyl cellulose. 
EUDRAGIT: 
      Eudragit is trademark of Rohm GmbH & Co. KG. Darmstadt in Germany, firstmarketed in 
1950s. Eudragit prepared by the polymerization of acrylic and Methacrylicacids or their esters, 
e.g., butyl ester or Dimethylaminoethyl ester. Eudragit introduced inUSPNF, BP, PhEur, Hand 
book of pharmaceutical excipients88. The Eudragit acrylicpolymers have a long history of use, 
the individual types and grades being introduced in the following chronological order:year of 
introduction; 
1972     Eudragit RS PO 
            Eudragit RL PO 
Glass transition temperature (Tg): 
       The glass transition temperature is an important factor for describing the physicalproperties 
of polymers. On a macroscopic level it describes the solidification of ananisotropic polymer 
melt. The glass transition temperature has far-reaching consequences,e.g. for film formation, 
melt processing and storage of finished pharmaceutical dosageforms. Plasticizers, solvents or 
residual solvents (including water) that act as plasticizersusually cause a reduction in glass 
transition temperature, which is specifically exploited inapplication formulations. Most common 
plasticizer for EUDRAGIT polymers is triethylcitrate (TEC). 
Physical and chemical properties; 
S. No Trade name Solubility Description Applications 
1 Eudragit S 100 Soluble in intestinal-
fluid from pH 7 
Anionic, white free 
flowing 
powders5 
Enteric 
coatings 
2 Eudragit RL PO High permeability Cationic, 
nonbiodegradable89 
Sustained 
release 
3 Eudragit RS PO Low permeability Cationic, 
nonbiodegradable89 
Sustained 
release 
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Figure (4.4): 
Different grades of Eudragit in oral solid dosage formulation 
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Drug Release Mechanism: 
Oral preparation for controlled release can be sub divided in systems where drug release from the 
dosage form is governed by the following principles: 
 
A. Dissolution 
B. Diffusion 
C. Osmotic Pressure 
D. Ion-Exchang 
E. Other Principle90 
Dissolution controlled dosage forms can be divided into reservoir and matrix system. Reservoir 
principle is given by a controlled release formulation comprising 400mg 5-ASA within an 
acrylic resin coat, Eudragit S91. 
Eudragit RS PO release the Carbamazepine drug by complex mixture of diffusion and Erosion 
mechanism92. 
Applications of Eudragit polymers: 
 Ophthalmic Drug Delivery 
 Buccal and Sublingual Drug Delivery 
 Gastrointestinal Drug Delivery 
 Intestinal Drug Delivery 
 Colon Drug Delivery 
 Transdermal Drug Delivery 
 Vaginal Drug Delivery 
 Gene Delivery 
 Vaccine Delivery 
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CHAPTER  5 
MATERIALS AND METHODS: 
Table (5.1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.No Name of the material Source/supplier/manufacturer 
1. Epalrestat Gift sampled from EXCELTIS 
2. Ethyl cellulose S d fine-CHEM LiMiTEd 
3. Eudragit Gift sampled from 
PHARMAFABRIKAN 
4. PVA CHEMICO LABORATORIES (P) 
LTD. MUMBAI 
5. Stearic acid HIMEDIA MUMBAI 
6. 
 
Methanol CHANGSHU Yangquan chemical 
CHINA 
7. SLS s d fine-CHEM Limited 
8. Chloroform HIMEDIA MUMBAI 
9. Di Chloro Methane CENTRAL DRUG HOUSE (P) 
LTD 
10. Sodium hydroxide Rankem  Laboratory  Ambattur 
11. Potassium Di hydrogen 
Ortho phosphate 
FISCHER CHEMIC Ltd 
Chennai 
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List of equipments used in the present study: 
Table (5.2) 
 Instruments Manufacturer 
Electronic weighing balance AUX 220 Shimadzu corporation, Japan. 
Magnetic stirrer Remi motors. 
Dissolution apparatus DISSO 2000, LABINDIA, Mumbai, India. 
UV-VIS Spectrophotometer SHIMAZHU UV-1700 pharma spec 
Hot air oven Micro Technik, Model-JEQ-3A, Amble, India. 
Rotary shaker RS-12,Remi equipments Ltd, Mumbai, India. 
Sonicater ELECTROSONIC INDUSTRIES. 
 
Construction of standard calibration curves94: 
       A standard calibration curve was plotted in methanol and water. accurately  weighed  20 mg 
of drug was transferred in to a 10 ml volumetric flask and this solution diluted in 100 ml distilled 
water. Taken 5 ml of in this solution and make up to 10 ml with distilled water. This gives a 
solution having concentration of 10µg/ml, of stock Epalrestat solution. From this primary stock 
solution  1ml was transferred into 10ml volumetric flask and made up to 10ml with distilled 
water to produce 1,2,3,4,5,6,7,8,9 &10 µg/ml solution respectively. The absorbance was 
measured at ƛ max 389 nm using UV spectrophotometer.  
Preparation Methods of  Micro spheres: 
Emulsion solvent evaporation technique93: 
Micro spheres were prepared by Solvent evaporation method. 
         Micro spheres were prepared by solvent evaporation method. Accurately weighed , 
different quantities of polymer were dissolved in 10 ml of chloroform and DiChloromethane by 
using a stirrer. The drug was mixed with the polymer solution followed by stirring for 10 min.  
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The resulting dispersion was then poured in to 500 ml beaker containing the mixture of  200 ml 
poly vinyl alcohol (as continuous phase). and  2% of Sodium Lauryl Sulphate(SLS). A 
mechanical stirrer with a three bladed paddle was used for stirring (at 1000 RPM) and it was 
continued for 2-3 hours, until complete evaporation of chloroform. After evaporation of 
chloroform , the micro spheres formed were filtered using filter paper and washed with water. 
The micro spheres were dried at room temperature for 24 hours and kept for further evaluations 
study. The prepared micro spheres were spherical and free flowing. The prepared micro spheres 
were analyzed for various Physico chemical properties such as entrapment efficiency, particle 
size distribution, in vitro dissolution studies, FT-IR and SEM. 
Table (5.3) 
FORMULATION COMPONENTS OF THE PREPARED EPALRESTAT MICRO 
SPHERES: 
Formu
lation 
Drug 
(mg) 
Ethyl 
cellulose 
(mg) 
Eudragit  
S-100 (mg) 
Eudragit  
RS 
100(mg) 
Eudragit  
RL 100(mg) 
Amount of 
chloroform
& DCM 
(ml) 
SLS 
(%) 
F1 500 600 400 - - 5:5 2 
F2 500 700 300 - - 5:5 2 
F3 500 800 200 - - 5:5 2 
F4 500 900 100 - - 5:5 2 
F5 500 600 - 400 - 5:5 2 
F6 500 700 - 300 - 5:5 2 
F7 500 800 - 200 - 5:5 2 
F8 500 900 - 100 - 5:5 2 
F9 500 600 - - 400 5:5 2 
F10 500 700 - - 300 5:5 2 
F11 500 800 - - 200 5:5 2 
F12 500 900 - - 100 5:5 2 
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Fourier Transforms Infrared Spectroscopy (FT-IR)99:  
The FT-IR spectrum of pure drug and the formulation were determined. 
The FT-IR was used for the analysis in the frequency between 4000-400cm-1 and 4cm-1 
resolutions the reagent were the means of  six determinations. The quality equivalent 2mg of 
pure drug was used for the study.  
Determination of Encapsulation efficiency (EE)94: 
        The encapsulation efficiency of the prepared micro spheres was determined by performing 
assay / drug content in the prepared microspheres. The microspheres from each batch  were 
taken. The microspheres were first crushed in a mortar and pestle and then 25 mg equivalent of 
the powder was taken in to the 10 ml volumetric flask. The volumetric flask then filled with 
methanol and Sonication for 1 min. And finally make up the volume. Further dilution made by 
100 % encapsulation efficiency. The samples were analyzed using UV-visible spectrophotometer 
at 389 nm. The Values are given in the table 6.2. 
The percent entrapment was calculated by using the following formula; 
 
In vitro drug release studies of prepared microspheres95: 
The in vitro dissolution studies were performed for the prepared microspheres using USP 
dissolution apparatus(apparatus 1),LABINDIA,DS-2000,Mumbai,India). The micro spheres 
were kept in the bowel of the dissolution medium. The dissolution medium consisted of 0.1N 
Hcl (900ml) for 2 hrs. Later the dissolution medium was replaced with 7.4 ph phosphate 
buffer(900 ml) at 100 rpm speed, maintained at 37.5°C. An aliquot (2ml) was withdrawn at 
specific time interval and filter through 0.45µ(Millipore)filter. After appropriate dilution the 
samples were analyzed and cumulative% of the drug release was calculated. 
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Kinetic analysis of  dissolution data96: 
Drug release kinetics and mechanism: 
To analyze the mechanism of drug release from the formulation, the dissolution profile of all the 
batches were fitted to zero order, 1st order , Higuchi and Peppas models to ascertain the kinetic 
modeling of drug release. 
Zero order: 
In many of the modified release dosage form particularly controlled or sustained dosage 
forms(those dosage forms that release the drug in planned, predictable and slower than normal 
manner) is zero order kinetics 
 Q = kot 
where, Q is the amount of drug release at time,  t & ko is the release rate constant. 
First order: 
The dissolution data was fitted to first order equation 
 ln(100-Q) = ln100 = k1t 
where k1 is the release rate constant  
Higuchi equation: 
A large number of modified released dosage form contain some sort of matrix system is such 
instances the drug dissolves from this matrix. The dissolution pattern of the drug is dictated by 
water penetration rate(diffusion control) and thus the following relationship applies. 
 Q = k2t1/2 
where Q is the % of drug release at time t & k2 is the diffusion rate constant. 
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Peppas equation: 
The Peppas model is widely used, when the release mechanism is not well known or more than 
one type of release could be involved. The semi-empirical equation shown as equation ; 
 Mt/M∞ = ktn 
Where Mt/M∞ is the fraction of drug released 'k' is the release constant, t is the release time. 
n is diffusion exponent, if n= 0.89, the release rate is zero order. If n = 0.45 the release is best 
explained by Fickian diffusion and if 0.45 < n < 0.89 then the release is through anomalous 
diffusion or non Fickian diffusion(swellable and cylindrical matrix). In this model a plot of log 
(Mt/M∞) Vs log (time is linear). 
Table (5.4) 
Release exponent Drug transport mechanism Rate as a function of time 
0.5 Fickian diffusion t-0.5 
S0.5< n < 1.0 Anomalous diffusion tn-1 
1.0 Case II transport Zero order release 
Higher than 1.0 Super Case II transport tn-1 
 
Particle distribution of microspheres97,98: 
Particle size analysis of microspheres was done by optical microscopy method by using a 
calibrated stage micrometer. Particle size was calculated by using equation 
 Xg = 10 x [(nix log Xi)/N] 
where, Xg is geometric mean diameter ni is number particle in range, Xi is the midpoint range  
and N is total number of particles. 
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Scanning Electron Microscopy (SEM): 
Morphological characterization of the micro spheres was done by using scanning electron 
microscope. 
Flow property studies: 
Angle of repose and compressibility index methods were carried out for studying  flow 
properties of microspheres which were prepared. 
Angle of repose100: 
Fixed funnel method was selected to find the angle of repose which employ a funnel that is 
secured with its tip at a given height (h), above  a plain of paper that is placed on a flat horizontal 
surface. Microspheres of different batches were carefully poured separately through the funnel 
until the apex of the conical pile just touches the tip of the funnel, 'r' being the radius of the base 
of the conical pile. Angle of repose was found out by using the formula given below: 
tan  = h/r 
 = tan-1(h/r) 
Stability study101: 
         Formulation were stored at 4°C in freeze, room temperature and at 60°c in hot air oven. 
After 30 days of storage, the formulation were observed physically and no color change and 
hardness was perceptible. the content of Epalrestat in all formulations at various intervals of 10, 
20 and 30 days calculated.  
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CHAPTER 6 
RESULT AND DISCUSSION'S: 
Standard calibration curve for Epalrestat: 
The standard calibration curve of Epalrestat was developed in media such as methanol and water 
and the water measured at 389 nm. Standard graph of Epalrestat shows linearity in the 
concentration range of 1-10 µg/ml with correlation coefficient of 0.999. 
Table (6.1) 
Concentration (µg/ml) Absorbance 
0 0 
1 0.105 
2 0.167 
3 0.227 
4 0.287 
5 0.347 
6 0.404 
7 0.465 
8 0.523 
9 0.587 
10 0.646 
 
 
 
 
 
 
Figure (6.1) 
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Table(6.2) 
Determination of Encapsulation efficiency (EE): 
Formulation Drug content in 100 mg of 
micro spheres 
Encapsulation Efficiency (%) 
F1 10.4 52 
F2 13.8 69 
F3 16 80 
F4 16.2 81 
F5 15.4 77 
F6 16.2 81 
F7 18.3 94 
F8 18.9 94.5 
F9 14.1 70.5 
F10 15.6 78 
F11 16.8 84 
F12 19.2 96 
 
The drug content was determined and finally encapsulation efficiency was calculated. The  
encapsulation efficiency for the microspheres prepared with Eudragit S 100 (F1to F4)was in the 
range of  52 to 81%. The encapsulation efficiency for the microspheres prepared with Eudragit 
RS 100 (F5 to F8) was in the range of   77 to 94.5%. The microspheres prepared with Eudragit 
RL 100 (F9 to F12) was in the range of   70.5 to 96%.Highest entrapment was observed in the 
microspheres prepared with Eudragit RL 100. However the particle size also changed with 
polymer might be due to change in the droplet formation in the emulsification process. The 
average particle size distribution of microspheres was given in the Table 6.27. 
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In vitro drug release studies: 
The in vitro dissolution studies were performed for the prepared microspheres  using dissolution 
apparatus (LABINDIA,DS 2000, Mumbai, India). The microspheres were kept in the  bowel of 
the dissolution medium. The dissolution medium consisted of 0.1 N Hcl (900 ml) for 12 hours at 
100 rpm speed, maintained at 37+5°c. The microspheres were weighed as per drug content 
estimated earlier of  this chapter and subjected for the dissolution study.  
Table: 6.3 summarize the practical amount of microspheres taken for the dissolution study. 
In vitro dissolution of  formulation prepared with Eudragit S 100: 
The drug release from the microspheres prepared with Eudragit S 100 (F1) was found 
between 1 to 8 hours. The drug release for the microspheres prepared at (F2) to ( F4) was found 
more than 12 hours. This may be the reason due to Eudragit S 100 being a more soluble polymer 
in the pH above 7 has with  stand the acid pH but have dissolved in the alkaline pH. Due to this 
the microspheres have resulted in the formation of many pores in the matrix resulting in the 
leeching of much drug along with the dissolution medium which has much more space to enter 
into the matrix. In vitro dissolution showed that the drug release mainly depends upon the 
polymer concentration. As the Ethyl Cellulose  polymer proportion increases in the microspheres 
the release rate was delayed. The in vitro drug release was fitted to the various kinetic models. 
The drug release kinetics showed that the release was followed zero order.  
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Table (6.3) 
Cumulative % drug release of the Epalrestat micro spheres  prepared with  
Eudragit S100 (F1): 
Reagents 
 
Time (Hrs) 
 
%  Drug release 
(F1) 
 
0.1N Hcl 
 
 
0 0 
60 9.98 
120 20.21 
180 39.83 
240 42.02 
 
 
7.4 pH 
Phosphate buffer 
300 54.54 
360 60.98 
420 73.31 
480 81.84 
540 92.97 
600 93.28 
660 93.87 
720 94.42 
 
Table (6.4) 
Kinetic analysis of  dissolution data for formulation (F1): 
Formulation Zero order First order Higuchi Peppas  
R2 R2 R2 R2 N 
F1 0.999 0.943 0.921 0.998 1.031 
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Table (6.5) 
Cumulative % drug release of the Epalrestat micro spheres prepared with 
Eudragit S 100 (F2): 
 
 
Table (6.6) 
Kinetic analysis of  dissolution data for formulation (F2): 
Formulation Zero order First order Higuchi Peppas  
 R2 R2 R2 R2 N 
F2 0.999 0.953 0.916 0.997 1.018 
 
 
Reagents 
 
Time Hrs) 
 
% Drug release 
(F2) 
 
 
0.1 N Hcl 
0 0 
60 7.58 
120 14.16 
180 23.74 
240 29.32 
 
 
 
7.4 pH  
Phosphate buffer 
300 38.90 
360 44.84 
420 55.60 
480 60.74 
540 67.89 
600 76.90 
660 82.83 
720 91.08 
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Table (6.7) 
Cumulative % Drug release of the Epalrestat micro spheres prepared with 
Eudragit S 100 (F3): 
Reagents Time (Hrs) 
 
% Drug release 
(F3) 
 
 
0.1 N Hcl 
0 0 
60 7.25 
120 13.80 
180 22.01 
240 28.03 
 
 
 
7.4 pH 
 Phosphate buffer 
300 36.55 
360 43.08 
420 51.92 
480 57.30 
540 65.43 
600 70.89 
660 78.02 
720 86.83 
 
Table (6.8) 
Kinetic analysis of  dissolution data for formulation (F3): 
Formulation Zero order First order Higuchi Peppas  
 R2 R2 R2 R2 N 
F3 0.998 0.971 0.919 0.998 1.008 
 
 
61 
AKCP  DEPARTMENT OF PHARMACEUTICS 
 
Table (6.9) 
Cumulative % Drug release of the Epalrestat micro spheres prepared with  
Eudragit S 100 (F4): 
Reagents Time (Hrs) 
 
% Drug 
release (F4) 
 
 
0.1 N Hcl 
0 0 
60 7.08 
120 13.16 
180 22.21 
240 29.32 
 
 
7.4 pH  
Phosphate buffer 
300 36.40 
360 40.48 
420 49.86 
480 55.64 
540 63.02 
600 64.80 
660 75.87 
720 83.09 
 
Table (6.10) 
Kinetic analysis of  dissolution data for formulation (F4): 
Formulation Zero order First order Higuchi Peppas  
 R2 R2 R2 R2 N 
F4 0.999 0.972 0.916 0.997 1.002 
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Figure (6.2) 
 
Cumulative % Drug release (vs) Time plot of the Epalrestat microspheres 
prepared with Eudragit  S 100 
Figure (6.3) 
 
Log % Drug remaining  (vs) Time plot of the Epalrestat microspheres prepared 
with Eudragit S 100. 
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Figure(6.4) 
 
Cumulative % Drug release (vs) Square root of time plot of the Epalrestat microspheres 
prepared with Eudragit S 100 
Figure(6.5) 
 
Log cumulative % Drug release  vs. Log time plot of the Epalrestat microspheres  
prepared with Eudragit S 100 
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In vitro dissolution of  formulation prepared with Eudragit RS 100: 
The drug release from the micro spheres prepared with Eudragit S 100 was found 
between 1 to 10 hours for the micro spheres prepared at (F5). The drug release for the micro 
spheres prepared at (f6) to (F8) was found more than 12 hours. This may be the reason due to 
Eudragit RS 100 has with stand the acid pH as well as alkali pH. Because this polymer have pH 
independent property. Due to this the microspheres have resulted in the formation of much pores 
in the matrix resulting in the leeching of much drug along with the dissolution medium which 
has much more space to enter into the matrix. In vitro dissolution showed that the drug release 
mainly depends upon the polymer concentration. As the Ethyl cellulose polymer concentration 
increase the release rate was decreases. The in vitro drug release was fitted to the various kinetic 
models. The drug release kinetics showed that the release was followed zero order. The kinetics 
were best fitted to the Peppas order clearly indicates that the drug release was surface erosion 
mechanism. 
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Table (6.11) 
Cumulative % Drug release of the Epalrestat microspheres prepared with 
Eudragit RS 100 (F5): 
Reagents Time  
(Hrs) 
 
% Drug release 
(F5) 
 
0.1N Hcl 
 
 
 
0 0 
60 8.71 
120 17.04 
180 26.89 
240 33.91 
 
 
 
7.4 pH 
 Phosphate buffer 
300 43 
360 53.87 
420 64.02 
480 74.07 
540 83.27 
600 91.87 
660 92.09 
720 92.89 
 
Table (6.12) 
Kinetic analysis of  dissolution data for formulation (F5): 
Formulation Zero order First order Higuchi Peppas  
R2 R2 R2 R2 N 
F5 0.983 0.929 0.927 0.998 1.018 
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Table (6.13) 
Cumulative % Drug release of the Epalrestat micro spheres prepared with 
Eudragit RS 100 (F6): 
Reagents Time (Hrs) 
 
% Drug 
release (F6) 
 
 
0.1 N Hcl 
0 0 
60 6.92 
120 15.2 
180 22.07 
240 28.81 
 
 
 
7.4 pH  
phosphate buffer 
300 35.62 
360 44.10 
420 52.22 
480 58.81 
540 64.94 
600 74.27 
660 80.92 
720 86.92 
 
Table (6.14) 
Kinetic analysis of  dissolution data for formulation (F6): 
Formulation Zero order First order Higuchi Peppas  
 R2 R2 R2 R2 N 
F6 0.999 0.931 0.921 0.998 1.017 
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Table (6.15) 
Cumulative % Drug release of the Epalrestat microspheres prepared with 
Eudragit RS 100 (F7): 
Reagents Time (Hrs) 
 
% Drug release 
(F7) 
 
 
0.1 N Hcl 
0 0 
60 6.54 
120 13.92 
180 21.63 
240 26.91 
 
 
 
7.4 pH 
 Phosphate buffer 
300 33.63 
360 41.98 
420 48.12 
480 53.97 
540 64.01 
600 69.86 
660 75.92 
720 83.78 
 
Table (6.16) 
Kinetic analysis of  dissolution data for formulation (F7): 
Formulation Zero order First order Higuchi Peppas  
 R2 R2 R2 R2 N 
F7 0.999 0.938 0.918 0.998 1.015 
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Table (6.17) 
Cumulative % Drug release of the Epalrestat microspheres prepared with 
Eudragit RS 100 (F8): 
Reagents Time (Hrs) 
 
% Drug release 
(F8) 
 
 
0.1   N Hcl 
0 0 
60 6.24 
120 13.05 
180 19.87 
240 25.98 
 
 
 
7.4 pH  
phosphate buffer 
300 32.21 
360 39.04 
420 46.25 
480 52.89 
540 60.73 
600 66.84 
660 74.25 
720 81.78 
 
Table (6.18) 
Kinetic analysis of  dissolution data for formulation (F8): 
Formulation Zero order First order Higuchi Peppas  
 R2 R2 R2 R2 N 
F8 0.999 0.938 0.912 0.999 1.023 
 
 
69 
AKCP  DEPARTMENT OF PHARMACEUTICS 
 
Figure (6.6) 
 
Cumulative % Drug release (vs) Time plot of the Epalrestat micro spheres 
 prepared with Eudragit  RS 100 
Figure (6.7) 
 
Log Cumulative % Drug remaining  (vs) Time plot of the Epalrestat microspheres 
prepared with Eudragit  RS 100. 
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Figure (6.8) 
 
 
Cumulative % Drug release (vs) Square root of time plot of the Epalrestat microspheres 
prepared with Eudragit  RS 100. 
Figure (6.9) 
 
Log cumulative % release  (vs) Log time plot of the Epalrestat micro spheres   
prepared with Eudragit  RS 100 
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In vitro dissolution of  formulation prepared with Eudragit RL 100 : 
       The drug release from the micro spheres prepared with Eudragit RL 100 was found between 
1 to 12 hours for the micro spheres prepared at F(9). The drug release for the micro spheres 
prepared at (F10) to (F12) was found more than 12 hours. This may be the reason due to 
Eudragit RS 100 has withstand the acid pH as well as alkali pH. Because this polymer have pH 
independent property. Due to this the microspheres have resulted in the formation of much pores 
in the matrix resulting in the leeching of much drug along with the dissolution medium which 
has much more space to enter into the matrix. In vitro dissolution showed that the drug release 
mainly depends upon the polymer concentration. As the Ethyl cellulose polymer concentration 
increase the release rate was decreased. The in vitro drug release was fitted to the various kinetic 
models. The drug release kinetics showed that the release was followed zero order. The kinetics 
were best fitted to the peppas order clearly indicates that the drug release was  surface erosion 
mechanism. 
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Table (6.19) 
Cumulative % Drug release of the Epalrestat microspheres prepared with  
Eudragit RL 100 (F9): 
Reagents Time (Hrs) 
 
% Drug release 
(F9) 
 
 
0.1N Hcl 
 
 
 
0 0 
60 6.8 
120 14.21 
180 19.84 
240 26.92 
 
 
 
7.4 pH  
phosphate buffer 
300 34.87 
360 40.58 
420 46.89 
480 53.71 
540 60.13 
600 68.1 
660 73.80 
720 81.69 
 
Table (6.20) 
Kinetic analysis of  dissolution data for Formulation (F9): 
Formulation Zero order First order Higuchi Peppas  
R2 R2 R2 R2 N 
F9 0.959 0.941 0.943 0.999 0.986 
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Table (6.21) 
Cumulative % Drug release of the Epalrestat microspheres prepared with  
Eudragit RL 100 (F10): 
Reagents Time (Hrs) 
 
% Drug 
release (F10) 
 
 
 
0.1 N Hcl 
0 0 
60 5.94 
120 12.54 
180 17.98 
240 25.11 
300 30.93 
 
 
 
7.4 pH 
 phosphate buffer 
360 36.97 
420 44.12 
480 50.62 
540 56.54 
600 62.97 
660 68.72 
720 77.21 
 
Table (6.22) 
Kinetic analysis of  dissolution data for formulation (F10): 
Formulation Zero order First order Higuchi Peppas  
 R2 R2 R2 R2 N 
F10 0.998 0.905 0.922 0.999 1.022 
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Table (6.23) 
Cumulative % Drug release of the Epalrestat microspheres prepared with  
Eudragit RL 100 (F11): 
Reagents Time (Hrs) 
 
% Drug release 
(F11) 
 
 
 
0.1 N Hcl 
0 0 
60 5.20 
120 11.24 
180 17.52 
240 24.81 
 
 
 
 
7.4 pH  
phosphate buffer 
300 28.27 
360 34.91 
420 42.86 
480 47.92 
540 54.80 
600 59.91 
660 64.63 
720 71.89 
 
Table (6.24) 
Kinetic analysis of  dissolution data for Formulation (F11): 
Formulation Zero order First order Higuchi Peppas  
 R2 R2 R2 R2 N 
F11 0.999 0.926 0.922 0.998 1.048 
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Table (6.25) 
Cumulative % Drug release of the Epalrestat microspheres prepared with  
Eudragit RL 100 (F12): 
 
 
Table (6.26) 
Kinetic analysis of  dissolution data for Formulation (F12): 
Formulation Zero order First order Higuchi Peppas  
 R2 R2 R2 R2 N 
F12 0.999 0.947 0.924 0.999 1.089 
 
 
Reagents Time (Hrs) 
 
% Drug release 
(F12) 
 
 
 
0.1 N Hcl 
0 0 
60 4.32 
120 11.05 
180 16.89 
240 23.00 
300 27.25 
 
 
7.4 pH  
phosphate buffer 
360 33.63 
420 40.35 
480 46.27 
540 51.75 
600 56.89 
660 63.64 
720 69.21 
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Figure (6.10) 
 
 
Cumulative % Drug release (vs) Time plot of the Epalrestat microspheres  
prepared with Eudragit  RL 100 
Figure (6.11) 
 
Log % Drug remaining  (vs) Time plot of the Epalrestat microspheres  prepared with 
Eudragit  RL 100 
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Figure (6.12) 
 
 
Cumulative % Drug release (vs) Square root of time plot of the Epalrestat microspheres 
prepared with Eudragit  RL 100 
Figure (6.13) 
 
Log cumulative % Dug release  (vs) Log time plot of the Epalrestat microspheres prepared 
with Eudragit  RL 100 
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Table (6.27) 
Time taken for 30%, 50% & 70% Drug release for various  Formulation's: 
Formulations t30% values t50% values t70%values 
F1 209.79 349.65 489.51 
F2 238.09 398.82 555.55 
F3 252.1 420.16 588.23 
F4 260.86 437.78 608.69 
F5 212.76 354.6 496.45 
F6 245.9 409.83 573.77 
F7 258.62 431.03 603.44 
F8 265.48 442.47 619.46 
F9 267.857 446.428 625 
F10 283.0188 471.698 660.377 
F11 300 500 700 
F12 309.27 515.46 721.64 
 
From the above result, Eudragit RL 100 formulation (F9- F12) time taken for drug release 
(30%,50%,70%) were comparable to greater  than Eudragit S 100 (F1- F4), Eudragit RS 100 
(F5-F8) formulation's. 
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In-vitro drug release kinetics: 
The results of the in vitro drug release study obtained from various batches were plotted 
using model dependent kinetic models such as Zero-order kinetics, first-order kinetics, Higuchi’s 
matrix and Korsmeyer Peppas model to evaluate the release mechanism from Epalrestat 
microspheres. The kinetic model showing highest correlation coefficient was considered as the 
most appropriate model for the dissolution data. The best fit with the highest correlation 
coefficient was observed in the Korsmeyers-peppas model and zero-order release kinetics 
followed by Higuchi model, as given in the previous tables. The ‘n’ value of formulation was 
found to be 0.986 to 1.089 for the various batches indicating that the drug release was followed 
by anomalous (non-fickian)  case 2 or super case 2 diffusion. According to the relative rates of 
diffusion (Rdiff) and polymer relaxation (Rrelax) three classes of diffusion can be distinguished. 
If the value of n = 0.5 it indicates a Fickian diffusion mechanism (Case I) in which the rate of 
diffusion is much smaller than the rate of relaxation (Rdiff« Rrelax), system controlled by 
diffusion), ii) n = 1.0 indicates Case II, where the diffusion process is much faster than the 
relaxation process (Rdiff» Rrelax, system controlled by relaxation), iii) 0.5 < n < 1.0 indicates 
non-Fickian (anomalous) diffusion mechanism, which describes those cases where the diffusion 
and relaxation rates are comparable (Rdiff≈ Rrelax). If the values of n > 1have been observed, 
which are regarded as Super Case II kinetics. 
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Determination of particle size by sieving method: 
The weighed amount of prepared twelve batches of micro spheres were passed through 
the four sets of sieves of constant mesh size of  60/80, 80/100, 100/140,and 140/200. The weight, 
percentage recovery and particle size of micro spheres are tabulated in table. 
Table (6.28) 
Particle size determination of Epalrestat micro spheres by sieving method: 
 
 
Particle size analysis of different formulations of Epalrestat Microsphere was carried out using 
digital micrometer. Data is given in table 6.27. By increasing the concentration of Ethyl 
cellulose, the mean particle size of microspheres increased. From results it can be seen that larger 
microspheres were obtained by increasing the concentration of Ethyl cellulose. As the 
concentration of the Ethyl cellulose increases the particle size increases. 
 
S .No Formulation Particle size(µm) 
1 F1 171 
2 F2 165 
3 F3 153 
4 F4 167 
5 F5 135 
6 F6 122 
7 F7 119 
8 F8 105 
9 F9 98 
10 F10 83 
11 F11 75 
12 F12 50 
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stability study: 
Table (6.29) 
Stability studies of the Epalrestat micro spheres prepared with Eudragit S 100: 
Formulation Temperature 
(0°C) 
% of Epalrestat 
0 days 
 
10 
days 
20 
Days 
30 
Days 
F1 4 52 51.19 51.17 51.17 
Room temp 52 52 52 52 
60 52 51.16 51.12 51 
 
F2 
4 69 68.95 68.74 68.63 
Room temp 69 69 69 69 
60 69 68.25 67.56 65.23 
F3 4 80 79.69 79.25 79.10 
Room temp 80 80 80 80 
60 80 78.23 77.36 76.85 
F4 4 81 80.96 80 79.85 
Room temp 81 81 81 81 
60 81 80.25 79.56 78.21 
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Table (6.30) 
Stability study of the Epalrestat micro spheres prepared with Eudragit RS 100: 
Formulation Temperature 
0°C 
% of Epalrestat 
0  
Days 
10 
Days 
20  
Days 
30 
Days 
F5 4 77 76.95 76 75.89 
Room temp 77 77 77 77 
60 77 75.6 74.3 73.6 
 
F6 
4 81 80.95 80 79.56 
Room temp 81 81 81 81 
60 81 79.5 78.5 77.2 
F7 4 94 93.69 93 92.56 
Room temp 94 94 94 94 
60 94 92.5 91.5 90.23 
F8 4 94.5 94 93.35 93.12 
Room temp 94.5 94.5 94.5 94.5 
60 94.5 92.45 90.23 89.47 
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Table (6.31) 
Stability studies of the Epalrestat microspheres prepared with Eudragit RL 100: 
Formulation Temperature 
0°C 
% of Epalrestat 
0 
Days 
10 
days 
20 
Days 
30 
Days 
sF9 4 70.5 69.56 69 68.32 
Room temp 70.5 70.5 70.5 70.5 
60 70.5 69.32 68.21 67.23 
 
F10 
4 78 77.98 77 76.23 
Room temp 78 78 78 78 
60 78 77.51 76.25 75.62 
F11 4 84 83.69 83 82.95 
Room temp 84 84 84 84 
60 84 83.25 82.45 81.45 
F12 4 96 95.78 94.52 93.15 
Room temp 96 96 96 96 
60 96 95.68 94.12 93.65 
 
  Formulation were stored at 4°C in freeze, room temperature and at 60°c in hot air oven. After 
30 days of storage, the formulation were observed physically and no color change and hardness 
was perceptible. the content of Epalrestat in all formulations at various intervals of 10, 20 and 30 
days calculated. The result provide that the percentage of Epalrestat was not less than 4-6 % in 
all the formulations after storing different temperatures, as shown in table. 
 
       It reveals that there was no degradation of Epalrestat in all formulations when stored under 
room and freeze temperature but at elevated temperature, the little degradation was found. 
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Fourier Transforms Infrared Radiation measurement(FT-IR) 
 
 
FT-IR spectrum of  pure Epalrestat  drug 
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FT-IR Spectrum of  Drug with Eudragit S 100 
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FT-IR Spectrum of  Drug with Eudragit RL 100 
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FT-IR Spectrum of  Drug with Eudragit Rs 100 
 
FT-IR study on the selected formulation prepared with different polymer combinations such as 
ethyl cellulose Eudragit S 100, Eudragit  RS 100 & Eudragit RL 100. The spectrum peak point of 
the formulation were similar with that of the pure Epalrestat, this clearly indicating that there is 
no polymer interaction. 
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Flow property study: 
Angle of repose: 
S. No Batch of microspheres Angle of  Repose 
1 Pure drug 43.56° 
2 D:Ec:Eu S 100 (F1) 30.50° 
3 D:Ec:Eu S 100 (F2) 29.41° 
4 D:Ec:Eu S 100 (F3) 30.21° 
5 D:Ec:Eu S 100 (F4) 28.45° 
6 D:Ec:Eu RS 100 (F5) 32.14° 
7 D:Ec:Eu RS 100 (F6) 30.15° 
8 D:Ec:Eu RS 100 (F7) 25.23° 
9 D:Ec:Eu RS 100 (F8) 23.22° 
10 D:Ec:Eu RL 100 (F9) 30.44° 
11 D:Ec:Eu RL 100 (F10) 29.65° 
12 D:Ec:Eu RL 100 (F11) 25.32° 
13 D:Ec:Eu RL 100 (F12) 20.65° 
 
Batches { D:Ec:Eu S 100 (F1-F4), D:EC:Eu RS 100 (F5-F8), D:EC:Eu RL 100 (F9-F12) }were 
found to give the values   given in the table. value less than 30 is considered to give good flow 
property. So the Batch F5 formulations were gave poor flow property. 
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Scanning electronic microscopy (SEM): 
 
Scanning electronic microscopic photograph of  the microspheres prepared  
with Eudragit S 100 (F1) 
 
 
Scanning electronic microscopic photograph of  the  prepared cross section  
microspheres   with Eudragit  S 100(F1) 
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Scanning electronic microscopic photograph of  the microspheres prepared  
with Eudragit S 100 (F2) 
 
 
Scanning electronic microscopic photograph of  the prepared cross section  
microspheres with Eudragit S 100 (F2) 
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Scanning electronic microscopic photograph of  the microspheres prepared  
with Eudragit S 100 (F3) 
 
Scanning electronic microscopic photograph of  the prepared cross section 
 microspheres with Eudragit S 100 (F3) 
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Scanning electronic microscopic photograph of  the microspheres prepared 
 with Eudragit S 100 (F4) 
 
 
Scanning electronic microscopic photograph of  the  prepared cross section  
microspheres  with Eudragit S 100 (F4) 
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Scanning electronic microscopic photograph of  the microspheres prepared  
 with Eudragit RS 100 (F5) 
 
'Scanning electronic microscopic photograph of  the prepared cross section 
microspheres  with Eudragit RS 100 (F5) 
 
 
94 
AKCP  DEPARTMENT OF PHARMACEUTICS 
 
 
Scanning electronic microscopic photograph of  the microspheres prepared with 
Eudragit RS 100 (F6) 
 
 
Scanning electronic microscopic photograph of  the microspheres prepared  
with Eudragit RS 100 (F6) 
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Scanning electronic microscopic photograph of  the microspheres prepared  
 with Eudragit RS 100 (F7) 
 
 
Scanning electronic microscopic photograph of  the prepared cross section microspheres 
with Eudragit RS 100 (F7) 
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Scanning electronic microscopic photograph of  the microspheres prepared  
with Eudragit RS 100 (F8) 
 
Scanning electronic microscopic photograph of  the prepared cross section microspheres 
with Eudragit RS100 (F8) 
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Scanning electronic microscopic photograph of  the microspheres prepared  
with Eudragit RL 100 (F9) 
 
 
Scanning electronic microscopic photograph of  the prepared cross section microspheres  
with Eudragit RL 100 (F9) 
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Scanning electronic microscopic photograph of  the microspheres prepared  
with Eudragit RL 100 (F10) 
 
 
Scanning electronic microscopic photograph of  the prepared cross section microspheres  
with  Eudragit RL 100 (F10) 
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Scanning electronic microscopic photograph of  the microspheres prepared with 
 Eudragit RL 100 (F11) 
 
 
Scanning electronic microscopic photograph of  the  prepared cross section microspheres  
with  Eudragit RL 100 (F11) 
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Scanning electronic microscopic photograph of  the microspheres prepared with 
 Eudragit RL 100 (F12) 
 
Scanning electronic microscopic photograph of  the prepared cross section microspheres  
with  Eudragit RL 100 (F12) 
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 Micro spheres before dissolution study were only subjected to SEM study. The surface 
topography of the prepared micro spheres was investigated by SEM. The prepared micro spheres 
were found to be spherical with smooth surface. 
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SUMMARY 
 
 The prepared microspheres were analyzed for various Physico chemical properties such 
as entrapment efficacy, particle size , in-vitro dissolution studies, FT-IR, SEM. 
 The entrapment efficacy can be varied to  the changing the different kinds of polymers. 
The entrapment efficacy depends upon the some factors such as, nature of the polymer, 
RPM  of  the propeller, solubility of the drug , and concentration of surfactant. 
 Highest proportion of the microspheres was obtained in the range of 389 nm for all the 
formulations. The average percent of microspheres obtained at 389 nm not varied with 
the type of polymer used. 
 The drug release from the F1 formulation microspheres releases the more amount of drug 
in phosphate buffer solution.  
 The kinetics showed that the release was followed Zero order and it was best fitted 
koresmeyer - Peppas model clearly indicates that  the mechanism was erosion 
mechanism. 
 The drug release from the micro spheres prepared with Eudragit S 100 was found 
between 1 to 8 hours for the micro spheres prepared at (F1). The drug release for the 
micro spheres prepared at (f2) to (F4) was found more than 12 hours. 
 The drug release from the micro spheres prepared with Eudragit RS 100 was found 
between 1 to 10 hours for the micro spheres prepared at (F5). The drug release for the 
micro spheres prepared at (f6) to (F8) was found more than 12 hours. 
 The drug release from the micro spheres prepared with Eudragit RL 100 was found 
between 1 to 12 hours for the micro spheres prepared at F(9). The drug release for the 
micro spheres prepared at (F10) to (F12) was found more than 12 hours. 
 FT-IR Study on the selected formulations prepared with different polymers such as Ethyl 
cellulose , Eudragit S 100, Eudragit R 100 and Eudragit RL 100. The  Spectrum peak 
points of  the formulation were similar with that of pure Epalrestat, this clearly indicating 
that there is no drug polymer interaction. 
 In the SEM  photograph , the microspheres prepared with different polymers found 
spherical/round. The surface of the microspheres  was rough and observed some particles. 
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CONCLUSION 
 
Epalrestat microspheres were prepared using  Ethyl cellulose, Eudragit S 100 & Eudragit RL 
100. The result of drug release kinetics show zero order with erosion mechanism. 
 
From the FTIR study, it is observed that there was no interaction between the drug and polymers. 
 
Dissolution studied study showed that all the polymer combinations gave sustained release. 
Maximum drug release was from the formulation (Drug: Ethyl cellulose: Eudragit S 100) (F1). 
 
From the SEM, the morphological characterization of the microspheres was studied . 
 
The prepared microspheres were spherical and free flowing by flow property studies and particle 
size distribution. 
 
The research work gives some preliminary idea about the release of  Epalrestat embedded in the 
core system of microspheres. 
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CHAPTER  09 
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